


EDGE MEDICAL  
精锋医疗

深圳市精鋒醫療科技股份有限公司  
Shenzhen Edge Medical Co., Ltd.

(A joint stock company incorporated in the People's Republic of China with limited liability)

Stock Code : 2675

# 2026 Interim Report



# Contents

|                                                                            |    |
|----------------------------------------------------------------------------|----|
| Corporate Information                                                      | 2  |
| Financial Highlights                                                       | 4  |
| Chairman's Statement                                                       | 5  |
| Management Discussion and Analysis                                         | 9  |
| Corporate Governance and Other Information                                 | 31 |
| Review Report                                                              | 40 |
| Consolidated Statement of Profit or Loss                                   | 41 |
| Consolidated Statement of Profit or Loss and<br>Other Comprehensive Income | 42 |
| Consolidated Statement of Financial Position                               | 43 |
| Consolidated Statement of Changes in Equity                                | 45 |
| Condensed Consolidated Cash Flow Statement                                 | 47 |
| Notes to the Unaudited Interim Financial Report                            | 48 |
| Definitions                                                                | 61 |



# Corporate Information

## BOARD OF DIRECTORS

### EXECUTIVE DIRECTORS

Dr. Wang Jianchen (*Chairman of the Board*)  
Dr. Gao Yuanqian  
Ms. Wu Mengyuan

### NON-EXECUTIVE DIRECTORS

Mr. Sheng Li  
Mr. Chen Gang  
Mr. Qiu Xiang

### INDEPENDENT NON-EXECUTIVE DIRECTORS

Mr. Yang Fan  
Mr. Zhang Guoguang  
Mr. Lau Ying Kit

## SUPERVISORY COMMITTEE

Mr. Ye Guoqiang (*Chairman of the Supervisory Committee*)  
Mr. Zhang Xiangping  
Mr. Lin Mincai

## AUDIT COMMITTEE

Mr. Zhang Guoguang (*Chairman*)  
Mr. Sheng Li  
Mr. Lau Ying Kit

## REMUNERATION COMMITTEE

Mr. Yang Fan (*Chairman*)  
Ms. Wu Mengyuan  
Mr. Zhang Guoguang

## NOMINATION COMMITTEE

Mr. Zhang Guoguang (*Chairman*)  
Dr. Gao Yuanqian  
Mr. Yang Fan

## JOINT COMPANY SECRETARIES

Ms. Wu Mengyuan  
Mr. Li Kin Wai

## AUTHORIZED REPRESENTATIVES

Ms. Wu Mengyuan  
Mr. Li Kin Wai

## H SHARE REGISTRAR

### TRICOR INVESTOR SERVICES LIMITED

17/F, Far East Finance Centre  
16 Harcourt Road  
Hong Kong

## REGISTERED OFFICE

1501, Building A1  
Bay Area Future Science and Technology Park  
No. 2 Jigutian Road, Baolong Community  
Baolong Street, Longgang District  
Shenzhen, PRC

## PRINCIPAL PLACE OF BUSINESS AND HEAD OFFICE IN THE PRC

1501, Building A1  
Bay Area Future Science and Technology Park  
No. 2 Jigutian Road, Baolong Community  
Baolong Street, Longgang District  
Shenzhen, PRC

## PRINCIPAL PLACE OF BUSINESS IN HONG KONG

Room 1918, 19/F  
Lee Garden One  
33 Hysan Avenue  
Causeway Bay, Hong Kong

## COMPLIANCE ADVISOR

### SOMERLEY CAPITAL LIMITED

20/F China Building  
29 Queen's Road  
Central, Hong Kong

### AUDITOR

#### **KPMG**

*Certified Public Accountants*

*Public Interest Entity Auditor registered in  
accordance with the Accounting and Financial  
Reporting Council Ordinance*

8<sup>th</sup> Floor, Prince's Building

10 Chater Road

Central, Hong Kong

### HONG KONG LEGAL ADVISER

#### **Cleary Gottlieb Steen & Hamilton (Hong Kong)**

37/F, Hysan Place

500 Hennessy Road

Causeway Bay

Hong Kong

### COMPANY WEBSITE

<http://www.edgemed.cn>

### STOCK CODE

2675

### LISTING DATE

January 8, 2026

### PRINCIPAL BANKS

#### **BANK OF CHINA**

##### **SHENZHEN DAYUNCHENG BRANCH**

Unit A202-1, 102 Block A, Plant 3

Longgang Tian'an

Cyber Entrepreneurship Park

Huangge North Road

Longgang District, Shenzhen

PRC

#### **CHINA MERCHANT BANK**

##### **SHENZHEN LONGGANG BRANCH**

Room 102, 103, 104, Block A

Rongchao Yinglong Building

Longgang Center City

Longcheng Street

Longgang District, Shenzhen

PRC

# Financial Highlights

The following table sets forth our key financial data for the six months ended June 30, 2026, together with the comparative figures for the six months ended June 30, 2025 and the changes (expressed in percentages).

|                                                         | Six months ended<br>June 30, |                   | Changes<br>(%) |
|---------------------------------------------------------|------------------------------|-------------------|----------------|
|                                                         | 2026<br>(RMB'000)            | 2025<br>(RMB'000) |                |
| Revenue                                                 | <b>319,316</b>               | 149,383           | 113.8%         |
| Gross profit                                            | <b>204,628</b>               | 93,850            | 118.0%         |
| Loss before taxation                                    | <b>(19,254)</b>              | (89,065)          | (78.4%)        |
| Loss for the period                                     | <b>(19,254)</b>              | (89,087)          | (78.4%)        |
| Loss attributable to equity shareholders of the Company | <b>(19,254)</b>              | (89,087)          | (78.4%)        |
| Loss per share – Basic and diluted (RMB)                | <b>(0.05)</b>                | (0.25)            | (80.0%)        |

During the Reporting Period, the Group recorded revenue of RMB319.3 million, representing a significant increase of 113.8% as compared to the six months ended June 30, 2025, which is attributable to a rapid growth in the sales of our surgical robots in both domestic and overseas markets. Our gross profit margin increased from 62.8% for the six months ended June 30, 2025 to 64.1% for the six months ended June 30, 2026, reflecting our strong cost management capabilities.

During the Reporting Period, the Group's net loss substantially reduced by 78.4% to RMB19.3 million, as compared to a net loss of RMB89.1 million for the six months ended June 30, 2025. The substantial reduction in our net loss was primarily due to the significant increase in revenue, particularly driven by the increase in sales volume of our Edge Multi-Port Endoscopic Surgical Robot.

# Chairman's Statement

Dear shareholders, partners, colleagues, and peers in the healthcare industry,

On behalf of the Board, I am pleased to present to you the interim operating review of our Group for the six months ended June 30, 2026. The first half of 2026 marks a critical stage of development for our Company following its listing on the Main Board of the Hong Kong Stock Exchange, as the global endoscopic surgical robot industry enters a pivotal window for commercialization. Our Group has remained committed to its platform-based independent innovation strategy, balancing the deepening of its domestic market presence with global business expansion, and has achieved steady progress across multiple dimensions, including financial performance, domestic and overseas commercialization, product pipeline advancement, and AI technology exploration. The following is a report to our shareholders on the operations of our Group during the Reporting Period.

## **FINANCIAL PERFORMANCE: RAPID GROWTH IN SCALE WITH SIGNIFICANT REDUCTION IN LOSS**

During the Reporting Period, as commercialization continued to gain momentum, our Group's overall financial performance improved substantially, with significant growth in revenue and gross profit, a gross profit margin sustained at an industry-leading level, and continued improvements in cost efficiency. Loss narrowed substantially as our Group steadily advanced toward sustainable operations.

During the Reporting Period, our Group generated revenue of RMB319.3 million, representing a significant increase of 113.8% as compared to the corresponding period in 2025 and equivalent to approximately 70% of our Group's full-year revenue for 2025; gross profit amounted to RMB204.6 million, representing an increase of 118.0% year-on-year; and the overall gross profit margin rose to 64.1%, up by 1.3 percentage points from the same period last year, maintaining an industry-leading level. During the Reporting Period, we installed or delivered 58 units of our surgical robots globally, among which 9 units and 49 units were installed or delivered in China and for overseas end-users, respectively, bringing cumulative global installations or deliveries to 158 units. In terms of revenue composition, equipment sales remained as the primary source of revenue, while the proportion of revenue derived from consumables and services continued to rise steadily, further reinforcing the commercial closed loop of "installation – procedure volume – consumables repurchase."

While rapidly expanding in scale, our Group continued to pursue disciplined cost management, achieving dynamic optimization of total operating expenses, with the expense ratio continuing to decline and operational efficiency improving steadily. Driven by both commercialization scale expansion and enhanced expense control, our Group's net loss during the Reporting Period narrowed substantially by 78.4% year-on-year, demonstrating significant progress in loss reduction. Sufficient cash reserves provide solid support for our Group's continued investment in research and development, global market expansion and supply chain development.

### **COMMERCIALIZATION LAYOUT: ACCELERATING GLOBAL LAYOUT, WITH OVERSEAS MARKETS BECOMING THE CORE GROWTH ENGINE**

In the domestic market, we have continued to advance the installation and clinical application of our Core Products in top-tier Class III Grade A hospitals across the country. Our product portfolio, including multi-port endoscopic surgical robots, single-port endoscopic surgical robots and the single-port and multi-port integrated platform, has achieved commercial installation, and its clinical value has been widely recognized by domestic clinical experts. In China, we installed or delivered 9 units of our surgical robots during the Reporting Period, bringing cumulative domestic installations or deliveries to 55 units, placing us among the first tier of domestic surgical robot companies. During the same period, our surgical robots were deployed at a number of prestigious domestic hospitals, including Peking University People's Hospital, Jilin Provincial People's Hospital, and Women's Hospital, School of Medicine Zhejiang University.

In overseas markets, commercialization achieved multiple breakthroughs, and overseas markets have become the core driver of our Group's revenue growth. During the Reporting Period, we installed or delivered 49 units of our surgical robots overseas, bringing cumulative overseas installations or deliveries to 103 units. Our products have been deployed at leading hospitals globally, including Hospital Orizonti in Brazil, National Medical Institute of the Ministry of the Interior and Administration (PIM MSWiA) in Poland, IFO Istituti Fisioterapici Ospedalieri in Italy, and National Institute of Oncology in Hungary. During the Reporting Period, overseas revenue accounted for approximately 69.8% of total revenue, with the share of overseas revenue continuing to rise and the pace of global expansion accelerating.

Leveraging the comprehensive strengths of our product platform, our portfolio of single-port and multi-port endoscopic surgical robots has established differentiated competitive advantages in the overseas market. While consolidating our core business in mature markets, we are also actively expanding into emerging regions and continuing to advance the global commercialization of our domestically-developed surgical robot portfolio. The growth momentum of the overseas markets demonstrates the global competitiveness of domestically-produced surgical robots while paving the way for the long-term development of our Group.

### **R&D PIPELINE AND AI TECHNOLOGY EXPLORATION: STRENGTHENING THE PLATFORM FOUNDATION AND POSITIONING FOR NEXT-GENERATION INTELLIGENT SURGICAL ROBOTS**

We have consistently pursued a full-stack, in-house approach to the development of our underlying technologies. Building on our multi-port endoscopic surgical robots, single-port endoscopic surgical robots and the single-port and multi-port integrated platform, we continue to expand our surgical robot portfolio and strengthen our technological advantages. Beyond our mature commercialized products, pipeline projects such as the upgraded series of Edge Bronchoscope Robot are progressing steadily, broadening our Group's product offering and building up product reserves for future clinical applications.

On the AI technology front, our Group has been actively exploring the frontier "AI + surgical robots", combining artificial intelligence with surgical robot hardware, imaging systems and surgical workflows. Through industry collaboration and strategic investments, our Group has established a presence in AI foundation models for surgical robots and is exploring next-generation intelligent surgical robots. As of the date of this report, Edge Medical has completed its strategic investment in PrimalVerse (Beijing) Technology Co., Ltd. and has partnered with Tsinghua University's leading foundation model team to co-develop AI models for robotic surgery, advancing the surgical robot industry through deep integration of AI and surgical technologies.

We fully recognize that "AI + surgical robots" remains at an early stage of industry development, and that much of the underlying technology requires continued iteration. Our Group will advance the research, development and validation of these technologies at a pragmatic pace.

### **OPPORTUNITIES AND CHALLENGES: BROAD INDUSTRY PROSPECTS, COMMITMENT TO LONGTERMISM**

Looking ahead, the global minimally invasive surgical robot sector continues to grow rapidly, while industry competition is intensifying. We face significant opportunities as well as considerable challenges, including competition with global leaders in the high-end market, pricing pressure from intense domestic competition, and the impact of global economic and trade policy uncertainties on our overseas expansion.

## Chairman's Statement

Looking ahead to the second half of 2026, our Company will steadily advance its operations in the following directions:

First, our Company will deepen its presence in the domestic high-end medical market by strengthening clinical cooperation and academic collaboration with leading Class III Grade A hospitals across the country. Leveraging its established product portfolio, including multi-port endoscopic surgical robots, single-port endoscopic surgical robots and single-port and multi-port integrated platform, our Company will enhance its clinical influence and brand recognition at prestigious hospitals, expand adoption across multiple surgical specialties, broaden its domestic market coverage, and steadily increase its market share in core segments.

Second, our Company will accelerate overseas commercialization by building and optimizing its global distribution network, advancing product registration and market entry in key target markets, fully unlocking the growth potential of its overseas business, and reinforcing overseas markets as a core growth engine.

Third, our Company will maintain its ongoing R&D investments, continue to refine and enhance its existing product portfolio, systematically advance its R&D pipeline, pragmatically explore the integration of artificial intelligence with surgical robots, and further strengthen its core technological advantages through a platform-based architecture.

Fourth, our Company will remain committed to a high-quality development strategy. While maintaining rapid business growth, our Company will continue to improve operational efficiency and expense management, further strengthen the commercial closed loop of “installation – procedure volume – consumables repurchase”, and progress steadily towards sustainable profitability.

September 23, 2026  
Dr. Wang Jianchen  
Chairman of the Board

# Management Discussion and Analysis

## INDUSTRY OVERVIEW

During the Reporting Period, the global economy remained in a stage of concurrent recovery and restructuring, with monetary policies of major economies gradually entering an adjustment cycle. Despite ongoing challenges posed by the international trade environment and geopolitical dynamics, the surgical robot industry, as a key segment of high-end medical devices, driven by new quality productive forces, maintained strong development resilience and continued to serve as an important driver of global industrial upgrading.

China's economy sustained a steady and positive development trajectory, with the accelerated cultivation of new quality productive forces and the continued release of growth momentum in high-end manufacturing and strategic emerging industries. As the inaugural year of the 15th Five-Year Plan, 2026 marks a critical stage in the accelerated evolution of high-end medical devices from "domestic substitution" to "global competition," creating a more favorable development environment for the high-quality development of the high-end medical device industry.

The medical device industry in China has continued to receive strong policy-level support. Following the successful conclusion of the Action Plan for the High-Quality Development of the Medical Device Industry (2023-2025) 《醫療裝備產業高品質發展行動計劃(2023-2025年)》, China's independent innovation capability in high-end medical devices has been significantly enhanced, and the continued optimization of the registration and review mechanism has further accelerated the time-to-market for innovative products.

From the perspective of the industry's stage of development, the global surgical robot market has maintained steady growth. The European market has maintained steady growth, driven by continuous improvements in healthcare payment systems and the ongoing expansion of clinical applications. Emerging markets in Asia, Latin America, the Middle East and Africa are in a rapid development phase; as healthcare infrastructure continues to improve and minimally invasive surgical technologies become more widely adopted, demand for robot-assisted surgery continues to grow, providing broad room for the industry's long-term development.

Compared with mature global markets, robot-assisted surgery in China remains at a rapid development stage. Although domestic surgical robot products have achieved continuous technological breakthroughs in recent years and the number of robot-assisted surgical procedures has grown rapidly, overall clinical penetration rates remain significantly lower than those in developed countries in Europe and North America, with substantial room for further improvement. With the ongoing trends of population ageing and rising demand for quality healthcare, coupled with growing acceptance of robot-assisted surgery among surgeons, the scope of robot-assisted surgery is expected to progressively extend from highly complex procedures to a broader range of specialties and routine surgical procedures, with market demand expected to further increase.

## Management Discussion and Analysis

In terms of the policy environment, during the Reporting Period, medical service pricing reform was further advanced. The national healthcare security authorities issued the Guidelines on Projects of Pricing for Surgical and Therapy Supporting Items (Trial) 《手術與治療輔助操作類醫療服務價格項目立項指南(試行)》, which for the first time established unified standards for medical service items related to robot-assisted surgery, providing a policy basis for the development of a charging framework for robot-assisted surgical procedures and promoting the more standardized integration of robot-assisted surgical technology into clinical practice. Concurrently, with the gradual implementation of the Action Plan for Promoting Large-Scale Equipment Renewal and Consumer Goods Trade-In 《推動大規模設備更新和消費品以舊換新行動方案》 and relevant supporting policies, demand for medical equipment renewal at all levels of medical institutions has continued to be released, creating new market opportunities for domestic high-end medical device enterprises and further driving the increase in the market penetration rate of domestically manufactured surgical robots.

In terms of the competitive landscape, in recent years, domestic surgical robot enterprises have continued to accelerate technological innovation and commercialization, achieving continuous breakthroughs in system stability, user experience, instrument diversity and breadth of clinical application, and progressively gaining recognition from clinical experts and medical institutions. As China continues to encourage the domestic application of high-end medical devices, domestic brands have continued to strengthen their market competitiveness by leveraging rapid response capabilities, localized service systems and more competitive integrated solutions, with domestic substitution entering into an accelerated development phase.

### BUSINESS PROGRESS

Since our establishment in 2017, we have consistently adhered to a full-stack self-developed technological approach, dedicating ourselves to overcoming the core technical barriers of surgical robots. We have developed a product matrix characterized by the synergistic development of multi-port, single-port, and telesurgery systems, and extended our business reach into specialized fields such as bronchoscopic robots.

During the Reporting Period, we remained committed to a clinical-value-oriented approach, and continued to advance product research and development, commercialization expansion, clinical application and international market deployment along three strategic directions, namely “platform-based products, globalized commercialization and intelligent innovation”, achieving steady development following the Listing. In January 2026, we successfully completed our listing on the Main Board of the Stock Exchange, entering into the international capital markets and further enhancing our capital strength, brand influence and capability for international development. We continued to refine our globalized operating framework and promote the synergistic development of R&D innovation, market expansion and supply chain construction, thereby laying a more solid foundation for future large-scale commercialization.

## Management Discussion and Analysis

As a globally leading surgical robot manufacturer with a simultaneous presence across multiple technological directions of surgical robots, including multi-port endoscopic, single-port endoscopic, single-port and multi-port integrated platform, natural orifice and telesurgery, we have established a differentiated platform-based competitive position. During the Reporting Period, we continued to advance product registration, clinical application and commercialization, and expanded the application boundaries of robot-assisted surgery across multiple specialties including urology, general surgery, gynecology, thoracic surgery and respiratory intervention, thereby further strengthening our platform-based product competitive advantages.

During the Reporting Period, we recorded total revenue of RMB319.3 million, with revenue attributable to products sold to overseas end users reaching RMB222.8 million, representing approximately 69.8% of our total revenue. We also maintained a gross profit margin of 64.1% during the Reporting Period and our net loss decreased significantly from RMB89.1 million for the six months ended June 30, 2025 to RMB19.3 million for the same period of 2026, demonstrating the strength of our business model and our established capacity for sustainable growth.

Through the concerted efforts of all employees, we are progressing toward a new phase of scaled and sustainable development with greater operational resilience, reaffirming our core strategic philosophy that “industry leadership can only be achieved through continuous innovation, and that meaningful participation in the global marketplace can only be realized through a steadfast commitment to international expansion (唯有創新才能引領行業潮流, 唯有堅定出海, 才能融入世界脈搏)”.

### **PRODUCT PORTFOLIO CONTINUES TO EXPAND, FURTHER HIGHLIGHTING THE ADVANTAGES OF THE PLATFORM STRATEGY.**

During the Reporting Period, we continued to advance the construction of our product platform and further consolidated our competitive position. Unlike most enterprises in the industry that focus on a single product line, we have consistently adhered to a platform-based R&D strategy, continuously enhancing R&D efficiency and commercialization synergy through the sharing of underlying core technologies, system architecture collaboration and coordinated multi-product deployment. We have now established a product matrix comprising the Edge Multi-Port Endoscopic Surgical Robot, the Edge Single-Port Endoscopic Surgical Robot, the Edge Bronchoscope Robot, and the Edge Cloud Telesurgery System, covering the principal technological pathways and future development directions in robotic minimally invasive surgery. As of the date of this report, we have obtained registration approval for our core surgical robots, comprising Edge Multi-Port Endoscopic Surgical Robot and Edge Single-Port Endoscopic Surgical Robot, together with our single/multi-port integrated platform, in various countries and regions, including the United Kingdom, New Zealand, Saudi Arabia, and Australia.

## Management Discussion and Analysis

### **LARGE-SCALE APPLICATION IN TOP-TIER HOSPITALS WITH CLINICAL PROCEDURES SURPASSING 20,000 CASES.**

During the Reporting Period, the deployment of our surgical robots covered a number of Chinese hospitals, including Peking University People's Hospital, Jilin Provincial People's Hospital, Women's Hospital School of Medicine Zhejiang University. In overseas countries, our coverage included top-tier hospitals such as Hospital Orizonti in Brazil, National Medical Institute of the Ministry of the Interior and Administration (PIM MSWiA) in Poland, IFO Istituti Fisioterapici Ospedalieri in Italy, and National Institute of Oncology in Hungary. As of June 30, 2026, over 1,700 cases of robot-assisted clinical surgeries at Southern Medical University Zhujiang Hospital had been completed using our surgical robots, cementing its status as a benchmark for the high-quality and large-scale clinical deployment of domestically manufactured surgical robots. As of June 30, 2026, over 18,300 and 3,300 cases of robot-assisted clinical surgeries in China were completed using our Edge Multi-Port Endoscopic Surgical Robot and Edge Single-Port Endoscopic Surgical Robot, respectively. The exceptional clinical value, ultra-stable performance and reliability of our surgical robots have been well received by customers both domestically and internationally.

### **TELESURGERY HAS SCALED TO ROUTINE APPLICATIONS ACROSS MULTIPLE INSTITUTIONS.**

Leveraging our Edge Cloud Telesurgery System, we have progressed remote robotic surgery from technological validation towards routine clinical application. Cross-campus collaborations have been carried out at several national and regional medical centers in China, while application scenarios have been extended to cross-regional, cross-border and intercontinental settings, expanding remote surgical accessibility to previously underserved areas. During the Reporting Period, as disclosed in public news, a number of landmark remote surgeries were completed using our surgical robots and our Edge Cloud Telesurgery System, including a remote robot-assisted surgery at the Chinese PLA General Hospital, as demonstrated during CILR 2026 in Rome. As of June 30, 2026, over 700 cases of robotic telesurgeries were completed using our Edge Cloud Telesurgery System. These achievements have further demonstrated our strong capabilities in the field of telesurgery on a global scale.

## **OUR PRODUCTS AND PRODUCT PIPELINE**

Our Company has developed a comprehensive technology platform centered on surgical robots. Through continuous R&D and innovation, we continuously enhance product performance and clinical application capabilities. We have a pipeline of three products and product candidates covering various models at different development stages to capture the market potential in surgical robots, including Edge Multi-Port Endoscopic Surgical Robot and Edge Single-Port Endoscopic Surgical Robot for MIS, as well as Edge Bronchoscope Robot for non-invasive surgery.

## Management Discussion and Analysis

The following chart provides a summary of our major products and product candidates as at the date of this report.

| Product Name                                          | Model/Version         | Region | Surgical Application                                             | Classification | Design and Development                                     | Type Testing | Clinical Trial/<br>Clinical Evaluation | Registration | Upcoming Key Milestone<br>(Expected) |
|-------------------------------------------------------|-----------------------|--------|------------------------------------------------------------------|----------------|------------------------------------------------------------|--------------|----------------------------------------|--------------|--------------------------------------|
| ★<br>Edge Multi-Port<br>Endoscopic<br>Surgical Robot  | MP1000 (base product) | China  | Urologic surgery                                                 | Class III      | Registration approved by NMPA in December 2022             |              |                                        |              | -                                    |
|                                                       |                       |        | Gynecologic, general and thoracic surgery                        |                | Registration modification approved by NMPA in August 2023  |              |                                        |              | -                                    |
|                                                       |                       | Europe | Urologic, gynecologic, general and thoracic surgery              | Class II(b)    | Obtained CE Marking from EMA in March 2025                 |              |                                        |              | -                                    |
|                                                       |                       |        | Urologic, gynecologic, general, thoracic surgery and telesurgery |                | To apply for registration modification with NMPA           |              |                                        |              | To be approved in 2027Q2             |
|                                                       | MP1000 Plus           | China  | Urologic, gynecologic, general and thoracic surgery              | Class III      | Registration modification approved by NMPA in October 2023 |              |                                        |              | -                                    |
|                                                       | MP2000 series         | China  | Urologic, gynecologic, general and thoracic surgery              | Class III      | Registration modification approved by NMPA in July 2024    |              |                                        |              | -                                    |
|                                                       |                       | China  | Urologic, gynecologic, general, thoracic surgery and telesurgery | Class III      | To apply for registration modification with NMPA           |              |                                        |              | To be approved in 2027Q2             |
|                                                       | Upgraded model        | China  | Pediatric and cardiac surgery                                    | Class III      | Type testing                                               |              |                                        |              | To complete type testing in 2026Q4   |
|                                                       |                       | China  | Urologic, gynecologic, general and thoracic surgery              | Class III      | Type testing                                               |              |                                        |              | To complete type testing in 2026Q4   |
|                                                       |                       | Europe | Urologic, gynecologic, general and thoracic surgery              | Class II(b)    | Type testing                                               |              |                                        |              | To complete type testing in 2026Q4   |
| ★<br>Edge Single-Port<br>Endoscopic<br>Surgical Robot | SP1000 (base product) | China  | Gynecologic surgery                                              | Class III      | Approved by NMPA in November 2023                          |              |                                        |              | -                                    |
|                                                       |                       |        | Urologic, general surgery                                        | Class III      | Approved by NMPA in October 2024                           |              |                                        |              | -                                    |
|                                                       |                       | China  | Otorhinolaryngology (ENT), head and neck surgery                 | Class III      | Submitted the NMPA application in August 2025              |              |                                        |              | To be approved in 2027Q1             |
|                                                       |                       | China  | Thoracic surgery                                                 | Class III      | Approved by NMPA in March 2026                             |              |                                        |              | -                                    |
|                                                       |                       | Europe | Urologic, gynecologic, general and thoracic surgery              | Class II(b)    | Obtained CE Marking from EMA in October 2025               |              |                                        |              | -                                    |
|                                                       | Upgraded model        | China  | Pediatric surgery                                                | Class III      | Type testing                                               |              |                                        |              | To complete type testing in 2026Q4   |
|                                                       |                       | China  | Urologic, gynecologic, general and thoracic surgery              | Class III      | Submitted the NMPA application in 2026Q1                   |              |                                        |              | To be approved in 2027Q1             |
|                                                       |                       | Europe | Urologic, gynecologic, general, thoracic and pediatric surgery   | Class II(b)    | Type testing                                               |              |                                        |              | To complete type testing in 2026Q4   |
| Edge Bronchoscope<br>Robot                            | CP1000 (base product) | China  | Diagnosis and treatment of bronchus and pulmonary lesions        | Class III      | Approved by the NMPA in January 2025                       |              |                                        |              | -                                    |
|                                                       | Upgraded model        | China  | Diagnosis and treatment of bronchus and pulmonary lesions        | Class III      | Product development                                        |              |                                        |              | To initiate type testing in 2026Q3   |
|                                                       |                       | Europe | Diagnosis and treatment of bronchus and pulmonary lesions        | Class III      | Product development                                        |              |                                        |              | To initiate type testing in 2026Q3   |

★ Core Product    ■ Clinical Trials Required    ■ Clinical Trials Exempted

Our strong portfolio of surgical robot products and product candidates enables us to provide comprehensive solutions across a wide spectrum of MIS procedures. It is also noteworthy that the compatibility between Edge Multi-Port Endoscopic Surgical Robot and Edge Single-Port Endoscopic Surgical Robot by sharing the same surgeon's console and 3DHD vision system allows surgeons to easily switch between the two and facilitates the adoption of both by hospitals.

As a fast-growing surgical robot company, we focus on surgical robots and instruments for MIS, including multi-port endoscopic surgical robots and single-port endoscopic surgical robots. Beyond MIS, we also expand our product offering into non-invasive surgery by developing natural orifice surgical robots. Leveraging our proprietary core technology modules, we have built a comprehensive suite of surgical robot systems addressing a wide range of surgeons' and patients' clinical needs.

## Management Discussion and Analysis

### EDGE MULTI-PORT ENDOSCOPIC SURGICAL ROBOT – OUR CORE PRODUCT

Edge Multi-Port Endoscopic Surgical Robot is a robot-assisted device that is used to perform MIS using robotic, imaging and digital technologies. With its assistance, trained surgeons can easily manipulate the surgical instruments that are positioned inside the patient through small incisions to perform surgery while seated comfortably at a console viewing a high resolution 3D image of the surgical field. The motions of Edge Multi-Port Endoscopic Surgical Robot in the surgical field are analogous to the motions of a human wrist with tremor inherent in a surgeon's hand filtered out. It enables surgeons to perform complicated procedures with precision in narrow workspaces.

In August 2023, we received the registration approval from the NMPA for expansion of MP1000's clinical application in gynecology, general surgery and thoracic surgery, which made MP1000 the first domestically developed endoscopic surgical robot approved by the NMPA for applications in multiple surgical specialties, according to Frost & Sullivan. In October 2023 and July 2024, the NMPA approved our registration modification for an updated version of MP1000, also known as MP1000 Plus, and MP2000 series, the second generation of our MP1000, respectively. In March 2025, we obtained the CE Marking of MP1000 in the EU.

During the Reporting Period, we further advanced the domestic and overseas commercialization deployment of our Edge Multi-Port Endoscopic Surgical Robot. In the domestic market, we expanded its presence across national medical centers, national regional medical centers, provincial flagship hospitals and large Class III Grade A hospitals, facilitating the integration of robot-assisted surgery into routine multidisciplinary practice. We also strengthened clinical collaborations and academic promotion activities with leading hospitals, supporting the broader adoption of robot-assisted surgery.

In the overseas market, we secured new or deepened commercial installations in Italy, Spain, India and Turkey, extending our market coverage to Europe, Southeast Asia, the Commonwealth of Independent States, the Middle East and Africa. In particular, we achieved a cross-island deployment in Indonesia covering both the Surabaya and Medan regions. In Brazil, we established a multi-site commercialization network with coordinated development between training centers and clinical partner hospitals. As of June 30, 2026, we have obtained registration approvals for Multi-Port Endoscopic Surgical Robot in 37 overseas jurisdictions in Europe, Asia-Pacific, Middle East, Africa and South America, covering 63 countries and regions in total.

Our Edge Multi-Port Endoscopic Surgical Robot has been applied across multiple specialties including urology, general surgery, gynecology and thoracic surgery, with real-world clinical evidence accumulated in complex tumor resections, organ reconstruction and challenging minimally invasive surgeries. We currently focus on the development and expansion of clinical applications of Edge Multi-Port Endoscopic Surgical Robot for use in urologic, gynecologic, general and thoracic telesurgeries. With telesurgery capabilities, we expect our next generation of surgical robots to facilitate improved surgical outcomes for complex cases by enabling surgical collaboration among specialist surgeons from various medical specialties and geographical locations.

### EDGE SINGLE-PORT ENDOSCOPIC SURGICAL ROBOT – OUR CORE PRODUCT

Edge Single-Port Endoscopic Surgical Robot, our Core Product, is a robot-assisted device that is applied to perform MIS through a single small incision or natural orifice. All instruments are incorporated in a single robotic arm that operates through a cannula. It is complementary to Edge Multi-Port Endoscopic Surgical Robot with all instruments and the camera emerging through a single cannula and triangulated around the target anatomy, enabling surgeons to access narrow workspaces. Procedures conducted with our single-port endoscopic surgical robot involve fewer incisions, thereby minimizing surgical wounds on patients and rendering procedures less invasive. Patients are also expected to experience less blood loss, less pain during procedures, faster recovery and shorter hospitalization time.

In November 2023, we received the registration approval from the NMPA for SP1000, the first model of Edge Single-Port Endoscopic Surgical Robot, for application in gynecologic surgery. In October 2024, we received the registration approval from the NMPA for expansion of SP1000's clinical application in urologic surgery and general surgery. SP1000 is the first (but currently not the only) domestically-developed single-port endoscopic surgical robot approved by the NMPA covering three or more major surgical specialties, according to Frost & Sullivan. We started to commercialize Edge Single-Port Endoscopic Surgical Robot in China in 2024 and obtained the CE Marking of SP1000 in the EU in October 2025. As of June 30, 2026, we have obtained registration approvals for SP1000 in 39 countries or regions.

As a key representative of cutting-edge minimally invasive surgical technology, single-port robots offer clinical advantages such as “minimally invasive, higher precision, better cosmetic outcomes, and faster recovery,” making them an important technological direction driving innovation in complex minimally invasive surgeries. During the Reporting Period, our Edge Single-Port Endoscopic Surgical Robot achieved several landmark clinical breakthroughs, with a development focus on deepening commercialization in the domestic market while establishing clinical footholds in Europe. In the domestic market, we introduced our Edge Single-Port Endoscopic Surgical Robot to specialized obstetrics and gynecology medical institutions. In May 2026, our Edge Single-Port Endoscopic Surgical Robot was commercially installed and commissioned at the Yuhang Campus of the Women's Hospital, Zhejiang University School of Medicine, marking the first installation of our single-port robot in a specialized obstetrics and gynecology hospital in China. The first gynecological surgery using our SP1000 was subsequently completed, expanding the clinical application of domestically manufactured single-port robots into the treatment of gynecological benign and malignant diseases and complex minimally invasive surgeries. In terms of the overseas market, the first overseas clinical application of our Edge Single-Port Endoscopic Surgical Robot was completed at the National Medical Institute of the Ministry of the Interior and Administration in Poland, where three consecutive challenging urological surgeries were performed. This marked a key milestone in the product's transition from European regulatory approval to real-world clinical use. As of the date of this report, our Edge Single-Port Endoscopic Surgical Robot has been commercially launched in multiple countries and regions, including Thailand, Turkey, Hungary, Italy and Spain.

## Management Discussion and Analysis

Leveraging the Edge Single-Port Endoscopic Surgical Robot and in collaboration with clinical experts, we successfully completed multiple innovative surgical procedures, which not only demonstrate the technical adaptability of the Edge Single-Port Endoscopic Surgical Robot in confined anatomical spaces, multi-organ coordinated operations, and complex reconstruction scenarios, but also further validate the safety, feasibility, and clinical application potential of domestically manufactured single-port endoscopic surgical robots in complex surgical procedures. As clinical applications continued to expand, over 3,300 cases of robot-assisted clinical surgeries in China had been completed using our Edge Single-Port Endoscopic Surgical Robot as of June 30, 2026.

We currently focus on the development and expansion of clinical applications of Edge Single-Port Endoscopic Surgical Robot primarily in urology, gynecology, general surgery, and thoracic surgery, with exploratory applications in otorhinolaryngology. In the meantime, we are also advancing research on the single-port surgical paradigm. We continue improving the performance of Edge Single-Port Endoscopic Surgical Robot based on feedback collected from prior clinical trials and ongoing clinical studies. We seek to develop high-precision endoscopic tracking technology that delivers superior image guidance. In addition, we will continue pursuing a compact design for robotic systems, reducing bulky external components that lead to instrument crowding and collisions.

### **RELATIONSHIPS BETWEEN EDGE SINGLE-PORT AND MULTI-PORT ENDOSCOPIC SURGICAL ROBOTS**

Leveraging the synergistic development of Edge Single-Port Endoscopic Surgical Robot and Edge Multi-Port Endoscopic Surgical Robot, both of which have obtained approvals in application to the same indications in urology, gynecology, general surgery, and thoracic surgery, we have successfully built a synergistic product portfolio covering the Edge Single-Port Endoscopic Surgical Robot and Edge Multi-Port Endoscopic Surgical Robot. By sharing the same surgeon's console and vision system, this portfolio further reduces customers' procurement and maintenance costs, and enables surgeons to tailor the medical solutions based on the patients' clinical needs, allowing them to select the types of surgery and optimal surgical planning through either the Edge Single-Port Endoscopic Surgical Robot or Edge Multi-Port Endoscopic Surgical Robot.

#### **Complementary Functions**

Our self-developed multi-port and single-port endoscopic surgical robots complement each other by providing surgeons with a wide range of options based on their clinical needs in different surgical specialties. They share the same surgeon's console and 3DHD imaging system (except for the 3D electronic endoscope), but feature different structures of patient-side cart. According to Frost & Sullivan, there is no substitution relationship between multi-port endoscopic surgical robots and single-port endoscopic surgical robots, as they are providing available options for surgeons when performing surgeries in different clinical departments according to their respective advantages.

## Management Discussion and Analysis

With multiple robotic arms, the Edge Multi-Port Endoscopic Surgical Robot enables surgeons to perform complex surgical procedures in a wide range of specialties, including but not limited to urologic, general, gynecologic and thoracic surgery. It provides various instrument options, flexible port placement and large range of motion.

One of the major issues for robot-assisted surgery performed in very narrow surgical workspaces is instrument collisions. The single-arm structure of the patient-side cart of Single-Port Endoscopic Surgical Robot enables surgeons to perform surgeries in narrower workspaces. It effectively avoids such collision because its instruments and endoscope all emerge through a single cannula and are properly positioned around the target anatomy. It is more suitable for surgeries in which concentrated lesions typically need to be removed in a highly focused and narrow space, such as ovariectomy and ureterectomy. In addition, Single-Port Endoscopic Surgical Robot causes only a single small incision, which is suitable for surgical procedures where patients seek less trauma and little scarring, such as female patients who need to undergo gynecologic surgery.

In practice, whether to use multi-port endoscopic surgical robots or single-port endoscopic surgical robots in surgeries also depends on other factors, such as the location of lesion, surgeons' techniques and skills in performing robot-assisted surgery and patients' postoperative recovery requirements.

Building upon the synergistic development of the Edge Single-Port Endoscopic Surgical Robot and the Edge Multi-Port Endoscopic Surgical Robot, and with both having obtained identical approved indications in urology, gynecology, general surgery and thoracic surgery, we have successfully combined the Edge Single-Port Endoscopic Surgical Robot and the Edge Multi-Port Endoscopic Surgical Robot into an integrated product offering, whereby end users share the same surgeon's console and imaging system. This further reduces customers' procurement costs and maintenance service costs, and enables surgeons to adopt a "tailored-to-condition" approach, selecting the most appropriate surgical access route and the corresponding Edge Single-Port or Edge Multi-Port surgical robot treatment plan based on the patient's specific condition.

### **Selling Opportunities**

More importantly, we market our multi-port and single-port endoscopic surgical robots together as a package. We believe that having both provides hospitals and medical institutions with comprehensive capabilities to address diverse clinical needs, enabling surgical teams to select the optimal approach for each patient while expanding access to minimally invasive treatment options. Our single-port and multi-port integrated platform obtained CE certification in October 2025 and received NMPA certification in March 2026. Our Company officially promoted the commercialization of our single-port and multi-port integrated platform during the Reporting Period. Featuring the capability to seamlessly switch between single-port and multi-port configurations, the integrated platform can be adapted to a wide spectrum of surgical requirements, thereby providing medical institutions with more versatile and comprehensive minimally invasive surgical solutions.

## Management Discussion and Analysis

With respect to single-port endoscopic surgical robots, certain current limitations on applicable surgical procedures and technological constraints have resulted in a significantly smaller market size of single-port endoscopic surgical robots than multi-port endoscopic surgical robots. In addition, the market of single-port endoscopic surgical robots, being a newer type of surgical robots, is still at an early stage of development, especially in the domestic market. Additional marketing and promotion are needed to educate the hospitals about single-port robots' unique ability to conduct certain types of surgeries and their superior performance over multi-port surgical robots in other types of surgeries. We have overcome the current challenges in the following aspects:

- *Integrated functionality.* By combining medical science with engineering, we systematically studied single-port applications across surgical specialties. Our analysis of the visual-to-operational workspace relationship, including the 7-DOF arm, 3D vision system, and lesion location, enabled data-driven control of the arm's distal end and instruments. These patented technologies resolve the core challenge of consolidating multi-arm functionality into a single arm.
- *Dexterous multi-DOF robotic arm design.* The difficulty of designing the dexterous multi-DOF robotic arm is how to design a steel wire drive mechanism. We overcame the complexity by innovating instruments, optimizing the balance among flexibility, resistance, and strength. Our advanced patent-protected wire transmission mechanism in the SP1000 ensures precise, stable movement within the patient's body.
- *Advanced modeling and control.* We have formulated mathematical models and algorithms that fully consider the complex features of 7-DOF arm, the power transmission, the master-slave structure, and the locational relations between visual workspace and operational space.

In practice, hospitals purchasing Edge Multi-Port Endoscopic Surgical Robots often prefer our Edge Single-Port system over competitors'. Since both our multi-port and single-port systems share the same surgeon's console and 3DHD vision system (excluding the 3D electronic endoscope), hospitals only need to acquire the Edge Single-Port patient-side cart and any additional required components.

**WE MAY NOT BE ABLE TO SUCCESSFULLY MARKET OUR CORE PRODUCTS IN OVERSEAS MARKETS AS PLANNED, OR SUCCESSFULLY DEVELOP OR MARKET THE EXPANSION OF SURGICAL APPLICATIONS OF OUR CORE PRODUCTS AND OTHER PRODUCT CANDIDATES IN CHINA OR IN OVERSEAS MARKETS. SHAREHOLDERS AND OTHER POTENTIAL INVESTORS OF THE COMPANY ARE ADVISED TO EXERCISE CAUTION WHEN DEALING IN OUR SHARES.**

### EDGE BRONCHOSCOPE ROBOT

Besides our Core Products, Edge Bronchoscope Robot, a natural orifice surgical robot for natural orifice transluminal endoscopic surgery, or NOTES, also plays an important role in our product portfolio. It is designed for diagnostic and therapeutic bronchoscopic procedures by navigating the lung periphery with a flexible robotic endoscope. As our robotic technology overcomes limitations of the reach of conventional bronchoscopy and allows the localization and diagnosis of the most difficult-to-reach lesions, it provides an effective method of taking biopsies of lung lesions and diagnosing smaller lung lesions at an earlier stage in lung disease, in particular peripheral lung cancer.

Edge Bronchoscope Robot is regulated as a Class III medical device in China. In January 2025, we obtained the Class III medical device registration certificate of CP1000, the first model of our Edge Bronchoscope Robot and the first domestically-developed dual-arm bronchoscope robot. It was approved by the NMPA for application in preoperative planning of natural orifice bronchoscopy procedures and treatments. CP1000 provides bronchoscopic visualization of the patient's airways and access routes to assist physicians in navigating and positioning the bronchoscope.

Edge Bronchoscope Robot is primarily comprised of the following four components: controller, two-arm robot cart, image navigation cart and patient-side system, and catheter. The controller allows the physician to easily control the bronchoscope robot. The image navigation provides direct vision and navigation features. The patient-side system contains a magnetic navigation system, which provides the precise location with real-time observation of the position and orientation of the catheter end in the lung. The bronchoscope sheath, which has a relatively larger diameter, creates a stable base to support the bronchoscope's inner tube to advance beyond the bronchoscope sheath to enter deeper into the lung under the control by one of the robotic arms.

We started to commercialize our Edge Bronchoscope Robot in China in September 2025 and have completed our first commercial installation, which marks our official entry into the respiratory intervention sector. The hospitals where the Edge Bronchoscope Robot has been commercially installed have successfully completed multiple clinical applications, marking the Company's official entry into the respiratory intervention robotics sector and further broadening its product portfolio and future growth potential.

We continue improving the clinical performance of our Edge Bronchoscope Robot, which will incorporate technologies that further enhance the safety and accuracy of the bronchoscopy surgery, reach deeper regions within the lungs, as well as enhance operational precision, expand instrument compatibility, and improve user-friendliness. The improvements will include: (i) ultra-thin endoscope technology to reach more distal lung lesions and expand the range of surgical tasks; (ii) multimodal fusion positioning technology that is capable of more comprehensive and accurate intraoperative spatial information of the lung lesions; and (iii) an integrated diagnostic and therapeutic robotic surgery system that maximizes success rates of lung lesion ablation with lower occurrence of complications.

# Management Discussion and Analysis

## CUTTING-EDGE TECHNOLOGY

We continue to drive cutting-edge technological innovation in the field of surgical robotics, achieving multiple breakthroughs in areas including telesurgery, AI-assisted operations and next-generation minimally invasive surgical platforms. Guided by a strategy of independent R&D and forward-looking deployment, we continue to invest in core technological areas including control systems, precision mechanical design, intelligent algorithms, digital surgery and artificial intelligence, driving our surgical robots to evolve from precision execution platforms toward more intelligent, digitalized and platform-based systems. Leveraging our self-developed Edge Endoscopic Surgical Robot and Edge Cloud Telesurgery System, we have achieved the cross-regional application of robotic telesurgery and carried out telesurgeries in multiple hospitals. We have been developing our Edge Cloud Telesurgery System since 2021 and have reached major milestones. As of June 30, 2026, we had established remote control centers in eight provinces in China and performed telesurgeries in multiple provinces in China. These achievements demonstrate the capability of our Edge Cloud Telesurgery System to overcome significant geographic barriers while ensuring safe and effective surgery.

On the platform development front, we have continued to advance R&D across core robotic technologies. In March 2026, we received the registration approval from the NMPA for the integrated platform of our Edge Multi-Port Endoscopic Surgical Robot and Edge Single-Port Endoscopic Surgical Robot. During the Reporting Period, we further optimized our control algorithms, transmission systems, imaging systems and software platforms. As of the date of this report, we have established a comprehensive in-house R&D system encompassing robotic systems, control systems, core algorithms, surgical instruments and software platforms. By leveraging shared underlying architecture across product platforms, we have enabled efficient technology reuse and rapid iteration. During the Reporting Period, we also expanded our portfolio of robotic instruments and accessories, supporting complex procedures and multi-disciplinary robotic surgeries.

In July 2026, we completed a strategic investment in PrimalVerse (Beijing) Technology Co., Ltd., an AI enterprise specializing in multi-modal 4D world models, to enhance our capabilities in the integration of AI with surgical robots and explore embodied intelligent surgical robotic platforms. We believe world model technology will enhance robotic understanding of complex surgical environments, enabling smarter pre-operative planning, intra-operative assistance and surgeon-machine collaboration. The investment will enable the Company to establish a strategic presence in the application field of embodied intelligence for “AI + surgical robotics”, build upon its collaboration with the world model team, and drive the evolution of surgical robots from precise execution to intelligent surgical infrastructure capable of scenario understanding, risk prediction, and collaborative operation.

## Management Discussion and Analysis

Further, we continue to advance the research, development, and iteration of our next-generation MIS robot platform, establishing a product portfolio that includes multi-port endoscopic surgical robot, single-port endoscopic surgical robot, and natural orifice surgical robot. In particular, the single-port endoscopic surgical robot operates through a single incision or natural orifice, which can reduce tissue trauma, minimize intraoperative bleeding, and accelerate post-operative recovery, which demonstrates promising clinical application prospects across multiple specialties, including urology, gynecology, and general surgery. Through the continuous advancement of research and development in key technologies such as telesurgery, intelligent operation, and minimally invasive surgical platforms, our Company consistently enhances the intelligence and precision of its surgical robots, laying a technological foundation for the future development of telesurgery and intelligent surgery.

### RESEARCH AND DEVELOPMENT

We focus on developing innovative technologies for MIS. We believe that the success of our operations depends to a large extent on our ability to design and develop advanced surgical robots. We are engaged in ongoing research and development activities to deliver clinically advanced new products, to enhance our surgical robots' effectiveness, ease of use, safety, reliability, and to expand the applications of our surgical robots.

Since our inception in 2017, we have been establishing a synergistic R&D platform covering internal scientific research, clinical development, quality control and regulatory administration for complex high-performance medical devices with strong barriers to entry. This platform organically integrates talents from diversified professional backgrounds, covering mechanics, medicine, medical engineering, computer graphics, computer science, electronics, material science and artificial intelligence. With this platform, we are able to accelerate development processes, achieve cost-efficiency and promote product innovation.

### CAPABILITY ON COMMERCIALIZATION

During the Reporting Period, we continued to build and refine our commercialization system covering product access, marketing, clinical support, after-sales services and physician training. Adopting a clinically led commercialization approach, we leveraged clinical adoption and academic collaboration to enhance the penetration and utilization of our robotic systems across medical institutions. We further optimized our market positioning by focusing on key regions, leading hospitals and priority clinical specialties, strengthening coverage among core medical institutions in both domestic and overseas markets.

## Management Discussion and Analysis

As of June 30, 2026, in terms of market coverage, our surgical robots had achieved commercial deployment in 18 provinces and municipalities in China and had gradually expanded into overseas markets, forming an international presence across regions including Europe, Asia-Pacific, Middle East, Africa and South America. We had installed or delivered 158 units of our surgical robots globally as of June 30, 2026, among which, 55 units and 103 units were installed or delivered in China and for overseas end-users, respectively. During the Reporting Period, 58 units of our surgical robots were installed or delivered globally, among which, 9 units and 49 units were installed or delivered in China and for overseas end-users, respectively. To facilitate clinical application following the installation of our surgical robots, we have established a comprehensive and systematic surgeon training program, designed to enhance surgeons' proficiency in operating our surgical robots through clinical training, surgical demonstrations, and remote guidance. In addition, our Company has established a training center in Europe to provide systematic trainings to local surgeons, thereby accelerating the promotion and adoption of our surgical robotic products across hospital institutions.

Furthermore, by continuously expanding clinical application scenarios and strengthening our hospital collaboration network, our Company has continuously increased the penetration of its surgical robots in medical institutions. As the number of clinical surgery cases continues to grow, our Company's recognition among the surgeon community has also increased. As of June 30, 2026, over 18,300 and 3,300 cases of robot-assisted clinical surgeries in China were completed using our Edge Multi-Port Endoscopic Surgical Robot and Edge Single-Port Endoscopic Surgical Robot, respectively. This remarkable achievement further consolidates our foundation for commercialization in the surgical robot industry.

### MANUFACTURING AND SUPPLY CHAIN

As of June 30, 2026, we have established a comprehensive production system encompassing precision machining, core component assembly, system integration, and functional testing, incorporating a modular design approach that provides the flexibility to meet the production requirements of multiple product models and generations. Our manufacturing facilities in Shenzhen had an annual production capacity of over 100 units. We are also in the process of establishing a new production facility with an annual capacity of approximately 350 units, which is expected to further enhance our manufacturing capabilities upon completion. In view of the increasingly complex international environment, we continued to place strong emphasis on supply chain security as part of our strategic management. We also enhanced our end-to-end operational framework covering R&D-to-mass production transition, manufacturing, quality control, and delivery services, while advancing digitalization and lean management to improve productivity. Aligned with international standards, we strengthened quality management across the full product lifecycle and global regulatory compliance to support reliable delivery and broader market access. Through independent R&D and strategic partnerships, we have secured stable supply of core components including robotic arms, optical systems, and control systems. We have also developed extensive collaborative relationships with over 100 domestic and international precision manufacturers, and built a secure and stable supply chain network supporting our global clinical operations.

## HUMAN RESOURCES AND PERSONNEL TRAINING

We consistently regard talent as the fundamental resource for driving technological innovation and business development. We continuously improve our human resources system to build a high-caliber and professional team. As at June 30, 2026, our Company had a total of 604 employees. We have continued to attract and recruit high-caliber professionals across key functional domains, including R&D, clinical support, market expansion, and production and manufacturing, and have continuously enhanced the professional competencies and collaborative efficiency of our employees through a structured combination of internal training and practical on-the-job experience. We have established a systematic employee development mechanism. Under this framework, regular technical, product, and clinical application trainings have been conducted, which continuously enhance employees' professional skills and industry expertise. These efforts are further supported by activities such as intraoperative support, clinical feedback collection, and the development of an internal curriculum system. In addition, by implementing long-term incentive mechanisms, including the Employee Incentive Scheme, we have further strengthened the stability and innovative drive of our core team. These measures provide a robust and sustainable talent foundation, supporting our ongoing technological breakthroughs and commercialization efforts in the high-end medical device sector, including the field of surgical robots.

Meanwhile, we continue to strengthen our clinical support and training teams, with plans to expand our headcount to provide clinical training and intraoperative support to surgeons, hospitals, and partners. In addition, we deliver internal training programs to enhance professional service capabilities and accelerate the clinical application and promotion of our products.

## INTELLECTUAL PROPERTY

We continuously strengthened our intellectual property protection system and improved our global patent portfolio. As of June 30, 2026, we held in aggregate 732 granted patents and patent applications globally. As of June 30, 2026, we had 30 trademarks registered in China and 18 trademarks registered overseas. As of the same date, we had 2 trademark applications pending in China. Through the ongoing maintenance of patent portfolio, trademark protection and trade secret management, we had established a relatively comprehensive intellectual property protection system, providing crucial support for the innovation of core technology and the commercialization of our products.

## OUTLOOK

In the second half of 2026, we will steadfastly execute the following strategic directions:

**Product portfolio expansion.** We will further advance the technological evolution of our multi-port endoscopic surgical robots, single-port endoscopic surgical robots, telesurgery system and bronchoscopy robots. Leveraging our existing platforms, we will develop new devices and functionalities, while continuing iterative upgrades in system performance and human-machine interaction to strengthen compatibility with complex surgeries across additional clinical scenarios.

## Management Discussion and Analysis

**Market penetration and globalization.** We will deepen domestic market coverage while strategically expanding into key overseas markets with significant growth potential for surgical robots. Through localized teams and services, we aim to establish our surgical robots as the preferred choice for surgeons and healthcare institutions worldwide. We will also strengthen collaborations with global clinical experts and institutions to steadily raise the proportion of revenue from overseas operations.

**Building a telesurgery ecosystem.** We will continue to develop a global telesurgery network centered on our Edge Cloud Telesurgery System, facilitating the transition of telesurgery from technological validation to routine clinical application. By leveraging our proven telesurgery capabilities, we aim to overcome geographical and resource barriers, expand access to advanced surgical care in underserved regions, and further consolidate our leadership in the telesurgery field.

**Driving intelligence through AI integration.** We will continue to increase R&D investments in AI, digital surgery, world models and intelligent robotics, driving the deep integration of AI capabilities with our robotic platforms. We will actively explore innovative AI applications in pre-operative planning, intra-operative navigation, intelligent decision support and human-robot collaboration, and forge partnerships with leading research teams and innovative enterprises to reinforce our technological layout for future intelligent surgery and facilitate the continued evolution of surgical robots from precision execution platforms toward fully intelligent surgical systems.

We fully recognize the challenges ahead, including competition with global leaders such as Intuitive Surgical in the high-end market, pricing pressure from intense domestic competition, and the impact of global economic and trade policy uncertainties on our overseas expansion.

Since the beginning of the year, we have achieved significant regulatory milestones. As of June 30, 2026, we have obtained registration approvals for MP1000 in 37 overseas jurisdictions covering 63 countries and regions in total, including the CE Marking in the EU. Building on this regulatory foundation, we plan to commercialize in the aforementioned regions, and further develop our telesurgery network. We will continue to increase R&D investments to drive the iterative upgrade of our next-generation intelligent robotic surgery platform.

Our management is confident that, supported by our technological expertise, comprehensive product portfolio, robust commercialization system and experienced team, we will continue to advance the adoption of domestically developed surgical robots, further enhance our international presence, and unlock new growth potential in the field of minimally invasive surgery.

## FINANCIAL REVIEW

### OVERVIEW

The following discussion is based on, and should be read in conjunction with, the financial data and the notes included elsewhere in this report.

### REVENUE

We generate revenue primarily from sales of surgical robot systems, instruments and accessories compatible with our surgical robots, and provision of maintenance and support services. Our revenue increased by 113.8% from RMB149.4 million for the six months ended June 30, 2025 to RMB319.3 million for the six months ended June 30, 2026, primarily due to a significant increase in the sales volume of the Edge Multi-Port Endoscopic Surgical Robot in overseas markets. The significant increase in sales volume in overseas markets was primarily attributable to our establishment of an overseas sales team and our finalization of distributor agreements. Based on the performance, clinical stability and marketing efforts of our surgical robots, the commercialization of our Edge Multi-Port Endoscopic Surgical Robot in overseas markets contributed substantially to the increase in revenue.

### COST OF SALES

Our cost of sales increased by 106.5% from RMB55.5 million for the six months ended June 30, 2025 to RMB114.7 million for the six months ended June 30, 2026. The increase in our cost of sales was primarily due to the increase in the sales volume of our Edge Multi-Port Endoscopic Surgical Robot in overseas markets, as well as the increase in our cost of sales resulting from the commercialization of our Edge Single-Port Endoscopic Surgical Robot in both domestic and overseas markets.

### GROSS PROFIT AND GROSS PROFIT MARGIN

Our gross profit increased by 118.0% from RMB93.9 million for the six months ended June 30, 2025 to RMB204.6 million for the six months ended June 30, 2026, primarily due to the significant increase in the sales volume of Edge Multi-Port Endoscopic Surgical Robot. Our gross profit margin increased from 62.8% for the six months ended June 30, 2025 to 64.1% for the six months ended June 30, 2026, primarily attributable to the economies of scale and improved production efficiency.

### RESEARCH AND DEVELOPMENT EXPENSES

Our research and development expenses decreased by 44.2% from RMB96.5 million for the six months ended June 30, 2025 to RMB53.8 million for the six months ended June 30, 2026. This decrease was primarily due to changes in research and development staff and a reduction in material expenses.

## Management Discussion and Analysis

The following table sets out the breakdown of the research and development expenses of the Group for the six months ended June 30, 2025 and June 30, 2026, respectively.

|                                            | For the six months ended June 30, |              |                |       |
|--------------------------------------------|-----------------------------------|--------------|----------------|-------|
|                                            | 2026                              |              | 2025           |       |
|                                            | <i>RMB'000</i>                    | %            | <i>RMB'000</i> | %     |
| Salaries, wages and other benefits         | <b>22,754</b>                     | <b>42.3</b>  | 41,018         | 42.5  |
| Materials and consumables used             | <b>22,616</b>                     | <b>42.0</b>  | 34,164         | 35.4  |
| Third-party service fees                   | <b>5,966</b>                      | <b>11.1</b>  | 2,396          | 2.5   |
| Depreciation and amortization              | <b>2,756</b>                      | <b>5.1</b>   | 3,954          | 4.1   |
| Clinical trial expenses                    | <b>554</b>                        | <b>1.0</b>   | 2,410          | 2.5   |
| Equity-settled share-based payment expense | <b>(2,084)</b>                    | <b>(3.9)</b> | 10,476         | 10.9  |
| Others                                     | <b>1,278</b>                      | <b>2.4</b>   | 2,084          | 2.1   |
| <b>Total</b>                               | <b>53,841</b>                     | <b>100.0</b> | 96,502         | 100.0 |

### ADMINISTRATIVE EXPENSES

Our administrative expenses decreased by 32.7% from RMB39.4 million for the six months ended June 30, 2025 to RMB26.5 million for the six months ended June 30, 2026, which was primarily due to our enhanced internal cost control and improved operational efficiency.

### SELLING AND MARKETING EXPENSES

Our selling and marketing expenses increased by approximately 49.1% from RMB58.7 million for the six months ended June 30, 2025 to RMB87.5 million for the six months ended June 30, 2026. This was primarily due to (i) the increased expense for our overseas promotional activities, and (ii) the increased headcount of our sales staff in connection with our increased marketing activities.

### FAIR VALUE CHANGES OF FINANCIAL ASSETS MEASURED AT FVPL

We recorded a net loss of RMB15.2 million on financial assets measured at FVPL for the six months ended June 30, 2026, as compared to a net gain of RMB8.7 million for the six months ended June 30, 2025. This was primarily due to a fair value loss on an investment in a private fund arising from market fluctuations, which were partially offset by a fair value gain on investment on net value-based wealth management products.

### NET LOSS

For the six months ended June 30, 2026, our net loss decreased by 78.4% to RMB19.3 million, as compared to a net loss of RMB89.1 million for the six months ended June 30, 2025. The substantial reduction in our net loss was primarily due to the significant increase in revenue while maintaining a steady increase in gross profit margin, particularly driven by the increase in sales volume of our Edge Multi-Port Endoscopic Surgical Robot and Edge Single-Port Endoscopic Surgical Robot and the enhancement of economies of scale.

### CASH AND CASH EQUIVALENTS

Our cash and cash equivalents increased significantly from RMB86.0 million as at December 31, 2025 to RMB1,260.1 million as at June 30, 2026, which was mainly due to the net proceeds raised from the Global Offering in January 2026. Our cash and cash equivalents are denominated in Renminbi.

### INVENTORIES

Inventories of our Company consist of raw materials, work-in-progress and finished goods. Our inventories increased by 16.2% from RMB136.1 million as at December 31, 2025 to RMB158.1 million as at June 30, 2026. The increase in our inventories was primarily due to the expected increase in sales volume of our surgical robots.

### TRADE AND OTHER RECEIVABLES AND CONTRACT ASSETS

Our trade and other receivables and contract assets increased by 22.9% from RMB230.5 million as at December 31, 2025 to RMB283.3 million as at June 30, 2026. The increase was driven by our revenue growth. For details of trade and other receivables, please refer to Note 10 in “Notes to the Unaudited Interim Financial Report”.

### FINANCIAL ASSETS MEASURED AT FVPL

Our financial assets measured at FVPL primarily consist of investment in short-term low-risk wealth management products and investment in private funds. Our financial assets measured at FVPL decreased by 26.2% from RMB727.8 million as at December 31, 2025 to RMB536.8 million as at June 30, 2026. The decrease was primarily due to a decrease in the financial assets such as wealth management products as a result of redemption of such financial assets.

### TRADE AND OTHER PAYABLES

Our trade and other payables consist of our trade payables to third-party suppliers, accrued payroll, and other payables and accrued charges. Our trade and other payables decreased by 41.1% from RMB135.5 million as at December 31, 2025 to RMB79.8 million as at June 30, 2026. The change was primarily due to the decrease in accrued payroll and other payables and accrued charges.

# Management Discussion and Analysis

## CAPITAL MANAGEMENT

Our objectives in the aspect of managing capital are to safeguard our ability to continue as a going concern in order to provide returns for shareholders and benefits for other stakeholders and to maintain an optimal capital structure to reduce the cost of capital. We actively and regularly review and manage our capital structure to maintain a balance between the higher shareholder returns that might be possible with higher levels of borrowings and the advantages and security afforded by a sound capital position, and make adjustments to the capital structure in light of changes in economic conditions.

## LIQUIDITY AND CAPITAL RESOURCES

As at June 30, 2026, our current assets were RMB2,358.2 million (as at December 31, 2025: RMB1,334.4 million), of which cash and cash equivalents amounted to RMB1,260.1 million, inventories amounted to RMB158.1 million, contract assets amounted to RMB8.0 million, trade and other receivables amounted to RMB255.4 million, prepayments amounted to RMB29.6 million, financial assets measured at FVPL amounted to RMB536.8 million and other current assets amounted to RMB110.1 million. As at June 30, 2026, our current liabilities were RMB121.0 million (as at December 31, 2025: RMB164.4 million), including trade and other payables of RMB79.8 million, contract liabilities of RMB7.8 million, lease liabilities of RMB10.9 million, and provisions of RMB22.5 million.

We primarily relied on capital contribution by our shareholders as our major sources of liquidity. We monitor and maintain a level of cash and cash equivalents deemed adequate to finance our operations and mitigate the effects of fluctuations in cash flows.

We adopt a prudent financial management approach for our treasury policy to ensure that our liquidity structure comprising assets, liabilities and other commitments is able to always meet our capital requirements. Taking into account the financial resources available to us, including cash and cash equivalents, available equity financing and the net proceeds from the Global Offering, our Directors are of the view that we have sufficient working capital for our operations.

## CAPITAL EXPENDITURE

For the six months ended June 30, 2026, our total capital expenditure was approximately RMB12.7 million, as compared to RMB1.7 million for the six months ended June 30, 2025. Our capital expenditures were primarily funded by internal resources, including cash and cash equivalents, and were mainly incurred to upgrade our production and research and development facilities to enhance our production capacity and operational efficiency.

## CAPITAL COMMITMENTS

As at June 30, 2026, we had capital commitments of RMB20.7 million (as at December 31, 2025: RMB0.2 million), which were primarily in connection with acquisition of property, plant and equipment.

### CONTINGENT LIABILITIES

As at June 30, 2026, our Company did not have any material contingent liabilities.

### GEARING RATIO

As at June 30, 2026, our gearing ratio, which is calculated as total liabilities divided by total assets, was 7.0%, as compared with 13.5% as at December 31, 2025. The decrease was primarily attributable to the significant increase in total assets in relation to the proceeds from the Global Offering.

### CURRENT RATIO

Our current ratio increased from 8.1 as at December 31, 2025 to 19.5 as at June 30, 2026, which was primarily attributable to the significant increase in cash and cash equivalents in relation to the proceeds from the Global Offering.

### MATERIAL ACQUISITIONS AND DISPOSALS AND SIGNIFICANT INVESTMENTS

During the Reporting Period, we neither had any significant investments, nor material acquisitions or disposals of subsidiaries, associates and joint ventures.

### FUTURE PLAN FOR MATERIAL INVESTMENTS OR CAPITAL ASSETS

As at June 30, 2026, save as disclosed in the section headed “Future Plans and Use of Proceeds” in the Prospectus and further explained in section headed “Use of Proceeds from the Global Offering” below, we had no future plan for material investments or capital assets.

### PLEDGE OF ASSETS

As at June 30, 2026, none of our assets was subject to any encumbrance, mortgage, lien, charge or pledge.

### FOREIGN EXCHANGE EXPOSURE

Our Company has transactional currency exposures arising from transactions by the group entities in currencies other than their respective functional currencies. Our Company is exposed to currency risk primarily from (i) sales which give rise to receivables that are denominated in a foreign currency, and (ii) investing activities that are denominated in US dollars. We currently maintain a foreign currency hedging policy. In addition, our management continuously monitors foreign exchange exposure and will consider hedging significant foreign currency exposure should the need arise.

### EMPLOYEES AND REMUNERATION POLICIES

As of June 30, 2026, we had 604 full-time employees (as of December 31, 2025: 602 employees). The staff costs, including salaries, wages and other benefits, contributions to defined contribution retirement plans as well as equity-settled share-based payment expenses, were approximately RMB104.7 million for the six months ended June 30, 2026.

## Management Discussion and Analysis

We hire employees based on their merits and we strive to offer equal opportunities to our employees regardless of gender, age, race, religion or any other social or personal characteristics. In compliance with the applicable labor laws, we enter into individual employment contracts with our employees covering matters such as wages, bonuses, employee benefits, confidentiality obligations, non-competition and grounds for termination. We emphasize career growth, mentorship and professional development for our employees. We strive to provide a safe working environment to our employees by implementing work safety guidelines, which set out safety practices, accident prevention and accident reporting.

Our employees' remuneration consists of salaries, bonuses, employees' provident fund and social security contributions and other welfare payments. In accordance with applicable Chinese laws, we have made contributions to social security insurance funds (including pension plan, unemployment insurance, work-related injury insurance, medical insurance and maternity insurance), supplemental medical insurance and housing funds for our employees. Furthermore, we provide various incentives and benefits to our employees, including competitive salaries, bonuses and share-based payment, particularly our core employees. The Employee Incentive Scheme was adopted on January 20, 2019, which was amended by the Board resolutions dated January 4, 2022. The purpose of the plan is to build an incentive mechanism for the management members and core employees of our Company to achieve the Company's sustainable and healthy development. The principal terms of the Employee Incentive Scheme are summarized in the section headed "Statutory and General Information — Further Information about our Directors, Supervisors, Senior Management and Substantial Shareholders — 5. Employee Incentive Scheme" in Appendix VI to the Prospectus.

# Corporate Governance and Other Information

## CHANGES IN DIRECTORS' AND SUPERVISORS' INFORMATION

Mr. Qiu Xiang was appointed as a non-executive director of New Century Healthcare Holding Co. Limited (HKEX: 1518), with effect from July 2, 2026. Mr. Lau Ying Kit resigned as the company secretary of Dalipal Holdings Limited (HKEX: 1921), with effect from September 1, 2026. Save as disclosed above, since the publication of the Company's 2025 annual report and up to the Latest Practicable Date, there had been no other changes to the Directors' or Supervisors' information which are required to be disclosed pursuant to Rule 13.51B(1) of the Listing Rules.

## INTERESTS AND SHORT POSITIONS OF THE DIRECTORS, SUPERVISORS AND THE CHIEF EXECUTIVE OF THE COMPANY IN THE SHARES, UNDERLYING SHARES AND DEBENTURES OF THE COMPANY AND ITS ASSOCIATED CORPORATIONS

As at June 30, 2026, the interests or short positions of our Directors and chief executive in the Shares, underlying shares and debentures of the Company or its associated corporations (within the meaning of Part XV of the SFO) which were required (i) to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests or short positions which they were taken or deemed to have under such provisions of the SFO), or (ii) to be entered into the register required to be kept by the Company pursuant to Section 352 of the SFO, or (iii) as otherwise notified to the Company and the Stock Exchange pursuant to the Model Code were as follows:

| Name of Director            | Capacity/Nature of interest <sup>(1)</sup> | Class of Shares | Number of Shares | Approximate percentage of shareholding in the relevant class of Shares <sup>(2)</sup> | Approximate percentage of shareholding in the Company <sup>(3)</sup> |
|-----------------------------|--------------------------------------------|-----------------|------------------|---------------------------------------------------------------------------------------|----------------------------------------------------------------------|
| Dr. Wang <sup>(4)(6)</sup>  | Beneficial interest/Interest in            | Unlisted Shares | 46,868,863       | 73.10%                                                                                | 11.96%                                                               |
|                             | controlled corporation/                    | H Shares        | 121,887,706      | 37.19%                                                                                | 31.10%                                                               |
|                             | Interest of spouse/Other                   |                 |                  |                                                                                       |                                                                      |
| Dr. Gao <sup>(5)(6)</sup>   | Beneficial interest/Interest of            | Unlisted Shares | 46,868,863       | 73.10%                                                                                | 11.96%                                                               |
|                             | spouse/Other                               | H Shares        | 121,887,706      | 37.19%                                                                                | 31.10%                                                               |
|                             |                                            |                 |                  |                                                                                       |                                                                      |
| Mr. Sheng Li <sup>(7)</sup> | Interest in controlled corporation/Other   | H Shares        | 31,181,895       | 9.51%                                                                                 | 7.96%                                                                |

## Corporate Governance and Other Information

### Notes:

- (1) All interests stated are long positions.
- (2) The calculation is based on 64,119,252 Unlisted Shares or 327,761,248 H Shares (including 1,818,900 treasury shares) issued by the Company as at June 30, 2026.
- (3) The calculation is based on the total number of issued shares of the Company as at June 30, 2026, being 391,880,500 Shares.
- (4) Dr. Wang is the sole general partner of Xieli Chuangfeng which held 10,708,126 H Shares as at June 30, 2026. By virtue of the SFO, Dr. Wang was deemed to be interested in the H Shares held by Xieli Chuangfeng as at June 30, 2026.
- (5) Dr. Gao is the spouse of Dr. Wang. By virtue of the SFO, Dr. Gao is deemed to be interested in the Shares in which Dr. Wang is interested.
- (6) As of June 30, 2026, 1,818,900 H Shares were repurchased and held as treasury shares by the Company. Dr. Wang and Dr. Gao are deemed to be interested in the Company's 1,818,900 treasury shares under the SFO due to their control of more than one-third of the voting power in the Company.
- (7) Each of Nanjing Jianye Sanzheng Zhengyun Equity Investment Partnership (Limited Partnership) (南京建邺叁正正昀股權投資合夥企業(有限合夥)) ("**Sanzheng Zhengyun**"), Robust Edge Investments Limited (健稜投資有限公司) ("**Robust Edge Investments**") and Centroid Investments Limited (心健投資有限公司) ("**Centroid Investments**") (collectively "**3H Health Entities**") is an investment vehicle operated under the brand of 3H Health Investment. Sanzheng Zhengyun is ultimately controlled by Mr. Sheng Li, and therefore Mr. Sheng Li is deemed to be interested in 11,691,424 H Shares held by Sanzheng Zhengyun under the SFO as at June 30, 2026. In addition, due to the common management of the 3H Health Entities, Mr. Sheng Li is also deemed to be interested in an aggregate of 19,490,471 H Shares held by 3H Health Investment Fund II, L.P., Robust Edge Investments and Centroid Investments as at June 30, 2026.

Save as disclosed above, as at June 30, 2026, so far as the Directors are aware, none of the Directors, Supervisors or the chief executive of the Company had or were deemed to have any interest or short position in any Shares or underlying Shares or debentures of the Company or its associated corporations (within the meaning of Part XV of the SFO) which was required (i) to be notified to the Company and the Stock Exchange under Divisions 7 and 8 of Part XV of the SFO; (ii) to be recorded in the register required to be kept by the Company under Section 352 of the SFO; or (iii) as otherwise notified to the Company and the Stock Exchange pursuant to the Model Code.

## SUBSTANTIAL SHAREHOLDERS' INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES

As at June 30, 2026, the interests of relevant persons (other than a Director, Supervisor or the chief executive of the Company) who had interests or short positions in the Shares or the underlying shares, which were required to be notified under Divisions 2 and 3 of Part XV of the SFO or recorded in the register required to be kept by the Company under Section 336 of the SFO, were as follows:

## Corporate Governance and Other Information

| Name of Shareholder                                                                                                                                                                                        | Nature of interest <sup>(1)</sup>                          | Number and class of Shares held | Approximate percentage of shareholding in the H Shares/ Unlisted Shares <sup>(2)</sup> | Approximate percentage of shareholding in total share capital of our Company <sup>(3)</sup> |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------|---------------------------------|----------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|
| Guadalupe Peak Limited <sup>(4)</sup>                                                                                                                                                                      | Beneficial Owner                                           | 4,741,110<br>Unlisted Shares    | 7.39%                                                                                  | 1.21%                                                                                       |
| Chengdu Mingsheng Investment Co., Ltd.<br>(成都明晟投資有限公司)<br>("Chengdu Mingsheng") <sup>(5)</sup>                                                                                                             | Beneficial Owner                                           | 17,504,640<br>H Shares          | 5.34%                                                                                  | 4.47%                                                                                       |
| GF Xinde Investment Management Co., Ltd.<br>(廣發信德投資管理有限公司) ("GF Xinde") <sup>(6)</sup>                                                                                                                     | Interests in controlled corporation/Other                  | 17,527,680<br>H Shares          | 5.35%                                                                                  | 4.47%                                                                                       |
| GF Securities Co., Ltd. (廣發證券股份有限公司)<br>("GF Securities") <sup>(6)</sup>                                                                                                                                   | Interests in controlled corporation/Other                  | 17,536,580<br>H Shares          | 5.35%                                                                                  | 4.47%                                                                                       |
| Dragon Warrior Investments Limited<br>("Dragon Warrior") <sup>(7)</sup>                                                                                                                                    | Beneficial interest/<br>Interest in controlled corporation | 19,580,471<br>H Shares          | 5.97%                                                                                  | 5.00%                                                                                       |
| Mr. Wang Shunlong (王順龍) <sup>(7)</sup>                                                                                                                                                                     | Interests in controlled corporation/Other                  | 31,271,895<br>H Shares          | 9.54%                                                                                  | 7.98%                                                                                       |
| Intelligent Spark Investment Pte. Ltd.<br>("Intelligent Spark") <sup>(8)</sup>                                                                                                                             | Beneficial owner                                           | 4,300,128<br>Unlisted Shares    | 6.71%                                                                                  | 1.10%                                                                                       |
| Suzhou Junlian Xiangdao Equity Investment Partnership (Limited Partnership)<br>(蘇州君聯相道股權投資合夥企業(有限合夥))<br>("Suzhou Junlian") <sup>(9)</sup>                                                                 | Beneficial owner                                           | 701,778<br>Unlisted Shares      | 1.09%                                                                                  | 0.18%                                                                                       |
|                                                                                                                                                                                                            |                                                            | 11,787,990<br>H Shares          | 3.60%                                                                                  | 3.01%                                                                                       |
| Social Security Fund Zhongguancun Independent Innovation Investment Fund (Beijing) Partnership Enterprise (Limited Partnership)<br>(社保基金中關村自主創新投資基金(北京)合夥企業(有限合夥)) ("Social Security Fund") <sup>(9)</sup> | Beneficial owner                                           | 272,913<br>Unlisted Shares      | 0.43%                                                                                  | 0.07%                                                                                       |
|                                                                                                                                                                                                            |                                                            | 4,584,216<br>H Shares           | 1.40%                                                                                  | 1.17%                                                                                       |

### Notes:

- (1) All interests stated are long positions.
- (2) The calculation is based on 64,119,252 Unlisted Shares or 327,761,248 H Shares (including 1,818,900 treasury shares) issued by the Company as at June 30, 2026.
- (3) The calculation is based on the total number of issued shares of the Company as at June 30, 2026, being 391,880,500 Shares.
- (4) Guadalupe Peak Limited is controlled by LYFE Capital Fund III (Dragon), L.P., which in turn is controlled by its general partner LYFE Capital Management Limited, a company controlled by Mr. Zhao Jin (趙晉). Therefore, LYFE Capital Fund III (Dragon), L.P., LYFE Capital Management Limited and Mr. Zhao Jin (趙晉) are deemed to be interested in the Shares held by Guadalupe Peak Limited under the SFO as at June 30, 2026.

## Corporate Governance and Other Information

- (5) Chengdu Mingsheng is controlled by Mr. Zhao Kai (趙凱). Therefore, Mr. Zhao Kai (趙凱) is deemed to be interested in the Shares held by Chengdu Mingsheng under the SFO as at June 30, 2026.
- (6) Guangfa Xinde Zhongheng Huijin (Longyan) Equity Investment Partnership (Limited Partnership) (廣發信德中恒匯金(龍岩)股權投資合夥企業(有限合夥)) (“**Zhongheng Huijin**”) is managed by GF Xinde, which is a wholly-controlled subsidiary of GF Securities, a PRC incorporated joint stock company whose shares are listed on the Shenzhen Stock Exchange (stock code: 000776) and the Stock Exchange (stock code: 01776). Therefore, GF Xinde and GF Securities are deemed to be interested in the Shares held by Zhongheng Huijin under the SFO as at June 30, 2026. In addition, as Guangyuan Zhonghe (Zhuhai) Investment Partnership (Limited Partnership) (廣遠眾合(珠海)投資企業(有限合夥)) (“**Guangyuan Zhonghe**”) has a de facto acting-in-concert relationship with GF Xinde, each of GF Xinde and GF Securities is deemed to be interested in the Shares beneficially owned by Guangyuan Zhonghe under the SFO as at June 30, 2026. Furthermore, GF Global Capital Limited (廣發全球資本有限公司) (“**GF Global**”) is a wholly-owned subsidiary of GF Holdings (Hong Kong) Corporation Limited, which is a wholly-owned subsidiary of GF Securities. Therefore, GF Securities is deemed to be interested in the 8,900 H Shares beneficially owned by GF Global under the SFO as at June 30, 2026.
- (7) Each of Sanzheng Zhengyun, Robust Edge Investments and Centroid Investments (collectively “**3H Health Entities**”) is an investment vehicle operated under the brand of 3H Health Investment. Robust Edge Investments is wholly-owned by 3H Health Investment Fund II, L.P., with 3H Health Investment GP II Ltd. acting as its general partner. Centroid Investments is wholly-owned by 3H Health Investment Fund I, L.P. with 3H Health Investment GP I Ltd. acting as its general partner. Both 3H Health Investment GP I Ltd. and 3H Health Investment GP II Ltd. are wholly-owned by Dragon Warrior, which in turn is wholly-owned by Mr. Wang Shunlong (王順龍). Therefore, Dragon Warrior is deemed to be interested in an aggregate of 19,490,471 H Shares held by 3H Health Investment Fund II, L.P. (as to 540,000 H Shares), Robust Edge Investments (as to 10,563,551 H Shares) and Centroid Investments (as to 8,386,920 H Shares), and Mr. Wang Shunlong (王順龍) is deemed to be interested in an aggregate of 19,580,471 H Shares held by 3H Health Investment Fund II, L.P., Robust Edge Investments, Centroid Investments and Dragon Warrior (as to 90,000 H Shares) under the SFO as at June 30, 2026. Sanzheng Zhengyun is managed by its general partner, Hainan Sanzheng. Sanzheng Zhengyun has one limited partner, Nanjing Jianye Sanzheng Shunxin Equity Investment Partnership (Limited Partnership) (南京建邺叁正順心股權投資合夥企業(有限合夥)) (“**Nanjing Sanzheng**”). Nanjing Sanzheng is ultimately controlled by Mr. Sheng Li, our non-executive Director, and therefore Mr. Sheng Li is deemed to be interested in 11,691,424 H Shares held by Sanzheng Zhengyun under the SFO as at June 30, 2026. In addition, due to the common management of the 3H Health Entities, Mr. Wang Shunlong (王順龍) is also deemed to be interested in the 11,691,424 H Shares held by Sanzheng Zhengyun as at June 30, 2026. Likewise, Mr. Sheng Li is also deemed to be interested in an aggregate of 19,490,471 H Shares held by 3H Health Investment Fund II, L.P., Robust Edge Investments and Centroid Investments as at June 30, 2026.
- (8) Intelligent Spark is wholly-owned by Boyu Capital Growth Fund I, Pte. Ltd., which is wholly-owned by Boyu Capital Growth Fund I, L.P.. The general partner of Boyu Capital Growth Fund I, L.P. is Boyu Capital Growth GP I, Ltd., which is wholly owned by Boyu Group, LLC. Boyu Group, LLC is controlled by XYXY Holdings Ltd., which is wholly owned by Mr. Xiaomeng Tong. Therefore, each of Mr. Xiaomeng Tong, XYXY Holdings Ltd., Boyu Group, LLC, Boyu Capital Growth GP I, Ltd., Boyu Capital Growth Fund I, L.P. and Boyu Capital Growth Fund I, Pte. Ltd. is deemed to be interested in the Shares held by Intelligent Spark under the SFO as at June 30, 2026.
- (9) Each of Suzhou Junlian and Social Security Fund is a limited partnership established in the PRC. The general partner of Social Security Fund is New Venture Capital Partnership (Limited Partnership) (北京君創勵新創業投資合夥企業(有限合夥)), whose general partner is Lhasa Junqi Enterprise Management Co., Ltd. (拉薩君祺企業管理有限公司) (“**Lhasa Junqi**”). The general partner of Suzhou Junlian is Lhasa Junqi, a wholly-owned subsidiary of Legend Capital Co., Ltd. (君聯資本管理股份有限公司) (“**Legend Capital**”). Legend Capital is controlled by Beijing Juncheng Hezhong Investment Management Partnership (Limited Partnership) (北京君誠合眾投資管理合夥企業(有限合夥)) (“**Juncheng Hezhong**”) whose general partner is Beijing Junqi Jiarui Enterprise Management Co., Ltd. (北京君祺嘉睿企業管理有限公司) (“**Junqi Jiarui**”). Junqi Jiarui is controlled by Mr. Chen Hao (陳浩). Therefore, each of Mr. Chen Hao, Junqi Jiarui, Juncheng Hezhong, Legend Capital and Lhasa Junqi is deemed to be interested in the Shares held by Suzhou Junlian and Social Security Fund under the SFO as at June 30, 2026.

## Corporate Governance and Other Information

Save as disclosed above, as at June 30, 2026, so far as the Directors are aware, no other person (not being a Director, Supervisor or chief executive of the Company) had or was deemed to have any interest or short position in any Shares or underlying shares of the Company which was required to be notified under Divisions 2 and 3 of Part XV of the SFO or recorded in the register required to be kept by the Company pursuant to section 336 of the SFO.

### PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

During the Reporting Period, the Company repurchased a total of 1,818,900 H Shares on the Stock Exchange for an aggregate consideration of approximately HK\$68,004,284 before expenses. The repurchased 1,818,900 H Shares have been held as treasury shares by the Company as of the date of this report. The repurchase was effectuated by the Board for the enhancement of shareholder value in the long term. Details of the H Shares repurchased are as follows:

| Month of purchases during the Reporting Period | Share repurchased<br>No. of H Shares purchased | Consideration per Share      |                             | Aggregate consideration paid<br>(HK\$) |
|------------------------------------------------|------------------------------------------------|------------------------------|-----------------------------|----------------------------------------|
|                                                |                                                | Highest price paid<br>(HK\$) | Lowest price paid<br>(HK\$) |                                        |
| June 2026                                      | 1,818,900                                      | 39.00                        | 33.78                       | 68,004,284                             |
| <b>Total</b>                                   | <b>1,818,900</b>                               |                              |                             | <b>68,004,284</b>                      |

Save as disclosed above, neither the Company nor any of its subsidiaries has purchased, sold or redeemed any of the Company's listed securities (including sale of treasury shares) during the Reporting Period. As of June 30, 2026, 1,818,900 H Shares were purchased and held in treasury by the Company, representing approximately 0.56% of the total number of issued H Shares of the Company (excluding treasury shares) as at June 30, 2026. The Company intends to use the treasury shares for purposes in compliance with the Company's constitutional documents, the Listing Rules and any other applicable laws, rules and regulations.

### EMPLOYEE INCENTIVE SCHEME

The Company adopted a share incentive scheme on January 20, 2019, which was adjusted by the Board resolutions dated January 4, 2022 (the "**Employee Incentive Scheme**"). The terms of the Employee Incentive Scheme are not subject to the provisions of Chapter 17 of the Listing Rules as the Employee Incentive Scheme does not involve the grant of new Shares or awards by our Company after the Listing. The Employee Incentive Scheme will not cause any dilution of the shareholding of the Shareholders after the Listing given all underlying Shares of the awards granted under the Employee Incentive Scheme have been issued.

## Corporate Governance and Other Information

For more details of principal terms of the Employee Incentive Scheme, please refer to the paragraph headed “Further Information about our Directors, Supervisors, Senior Management and Substantial Shareholders – 5. Employee Incentive Scheme” in Appendix VI to the Prospectus.

### USE OF PROCEEDS FROM THE GLOBAL OFFERING

Our H Shares were listed on the Stock Exchange on January 8, 2026. The net proceeds received from the Global Offering (taking into account the full exercise of the over-allotment option and after deduction of the underwriting fees and commissions and other estimated related expenses payable by us in connection with the Global Offering) were approximately HK\$1,289.2 million.

As of June 30, 2026, the net proceeds utilized were approximately HK\$178.2 million and the remaining net proceeds were approximately HK\$1,111.0 million. We intend to continue to utilize the remaining net proceeds in the future for the purposes as set out in the Prospectus. The table below sets out the planned usage of the net proceeds from the Global Offering and actual usage up to June 30, 2026.

| Use of proceeds                                                                                                            | Allocation<br>(%) | Net proceeds<br>from the Global<br>Offering<br>(HK\$ in million) | Utilized<br>amount up to<br>June 30, 2026 | Unutilized<br>amount as at<br>June 30, 2026 | Expected timeline<br>for fully utilizing<br>the unutilized amount |
|----------------------------------------------------------------------------------------------------------------------------|-------------------|------------------------------------------------------------------|-------------------------------------------|---------------------------------------------|-------------------------------------------------------------------|
| Ongoing and planned R&D of<br>our Core Products                                                                            | 42.0              | 541.5                                                            | 51.3                                      | 490.2                                       | By December 31, 2028                                              |
| Commercialization of our Core Products                                                                                     | 20.0              | 257.8                                                            | 70.9                                      | 186.9                                       | By December 31, 2028                                              |
| Expansion of our manufacturing capacity                                                                                    | 10.0              | 128.9                                                            | 28.3                                      | 100.6                                       | By December 31, 2028                                              |
| R&D and commercialization of our other<br>products and product candidates                                                  | 8.0               | 103.1                                                            | 3.1                                       | 100.0                                       | By December 31, 2028                                              |
| Potential strategic acquisitions,<br>investments or collaborations in<br>the surgical robot industry and<br>related fields | 10.0              | 128.9                                                            | –                                         | 128.9                                       | By December 31, 2028                                              |
| For working capital and other general<br>corporate purposes                                                                | 10.0              | 128.9                                                            | 24.5                                      | 104.4                                       | By December 31, 2028                                              |
| <b>Total</b>                                                                                                               | <b>100%</b>       | <b>1,289.2</b>                                                   | <b>178.2</b>                              | <b>1,111.0</b>                              |                                                                   |

Notes:

- (1) The expected timeline for utilization of the unutilized proceeds disclosed above is based on the best estimation from the Board in accordance with latest information as at the date of this report.
- (2) Any discrepancies in this table between the total and sums of amounts are due to rounding.

### INTERIM DIVIDENDS

The Board did not recommend the distribution of an interim dividend for the six months ended June 30, 2026.

### AUDIT COMMITTEE

The Board has established the Audit Committee, which consists of two independent non-executive Directors, namely Mr. Zhang Guoguang (chairman of the Audit Committee) and Mr. Lau Ying Kit, and one non-executive Director, namely Mr. Sheng Li. The primary responsibilities of the Audit Committee are reviewing the financial position of the Company, reviewing the financial information of the Company, making judgments on the authenticity, completeness and accuracy of the financial information, and examining the implementation and effectiveness of the internal control systems. It is also mainly responsible for the communication between the Company and the external auditors and the supervision and verification of such communication, supervision of the internal audit, evaluation and improvement of the Company's internal control systems, and making recommendations in this regard, and assessing the risks of, among others, the Company's major investment projects in progress. The Audit Committee has reviewed the unaudited consolidated interim results of the Group for the Reporting Period and confirmed that the applicable accounting principles, standards and requirements have been complied with, and that adequate disclosures have been made.

In addition, the Company's independent auditor, KPMG, has performed an independent review of the Group's interim financial information for the Reporting Period in accordance with Hong Kong Standard on Review Engagements 2410 *"Review of Interim Financial Information performed by the Independent Auditor of the Entity"* issued by the Hong Kong Institute of Certified Public Accountants.

### COMPLIANCE WITH THE CORPORATE GOVERNANCE CODE

The Company's corporate governance practices are based on the principles and code provisions of the CG Code and the Company has adopted the code provisions as set out in the CG Code contained in Appendix C1 to the Listing Rules as its own code of corporate governance.

The Board is of the view that from the Listing Date to June 30, 2026, the Company has complied with all code provisions of the CG Code, save for the following.

## Corporate Governance and Other Information

Pursuant to the code provision set out in Part 2 of CG Code, companies listed on the Stock Exchange are expected to comply with, but may choose to deviate from the requirement that the responsibilities between the chairman and the chief executive officer (the “**CEO**”) should be segregated and should not be performed by the same individual. We do not have a separate chairman and CEO and Dr. Wang Jianchen (“**Dr. Wang**”) currently performs these two roles. Our Board believes that, in view of his experience, personal profile and his roles in our Company as mentioned above, Dr. Wang is the Director best suited to identify strategic opportunities and focus of the Board due to his extensive understanding of our business as our CEO. The Board also believes that vesting the roles of both chairman and CEO in the same person has the benefit of (i) ensuring consistent leadership within the Group, (ii) enabling more effective and efficient overall strategic planning and execution of strategic initiatives of the Board, and (iii) facilitating the flow of information between the management and the Board for the Group. The Board considers that the balance of power and authority for the present arrangement will not be impaired and this arrangement will enable the Company to make and implement decisions promptly and effectively. The Board will continue to review and consider splitting the roles of chairman of the Board and the CEO of the Company at a time when it is appropriate by taking into account the circumstances of the Group as a whole.

The Board will periodically review and enhance its corporate governance practices to ensure that the Company continues to meet the requirements of the CG Code.

### MODEL CODE FOR SECURITIES TRANSACTIONS

The Company has adopted the Model Code as its own code of conduct regarding the transactions of securities of the Company by its Directors, Supervisors and relevant employees who are likely to possess inside information concerning the Company’s securities.

Specific enquiry has been made to all Directors, Supervisors and relevant employees, and all of them have confirmed that they have complied with the Model Code from the Listing Date and up to the date of this report.

### PUBLIC FLOAT

Based on the information that is publicly available to the Company and within the knowledge of the Directors, at least 15% of the Company’s total issued H Shares had been held by the public as required by the Stock Exchange since the Listing Date and up to the date of this report.

### OTHER INFORMATION

The Company does not have any other disclosure obligations pursuant to Rules 13.20, 13.21 and 13.22 of Listing Rules.

### EVENTS AFTER THE REPORTING PERIOD

No material event affecting the Group has occurred since the end of the Reporting Period and up to the date of this report.

By Order of the Board

**Shenzhen Edge Medical Co., Ltd.**

深圳市精鋒醫療科技股份有限公司

**Dr. Wang Jianchen**

*Chairman of the Board and Executive Director*

September 23, 2026

# Review Report

## **Review report to the board of directors of Shenzhen Edge Medical Co., Ltd.**

*(incorporated in the People's Republic of China with limited liability)*

### **INTRODUCTION**

We have reviewed the interim financial report set out on pages 41 to 60, which comprises the consolidated statement of financial position of Shenzhen Edge Medical Co., Ltd. (the “Company”) as of June 30, 2026 and the related consolidated statement of profit or loss, consolidated statement of profit or loss and other comprehensive income, consolidated statement of changes in equity and condensed consolidated cash flow statement for the six-month period then ended, and explanatory notes. The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited require the preparation of an interim financial report to be in compliance with the relevant provisions thereof and International Accounting Standard 34 *Interim financial reporting* as issued by the International Accounting Standards Board. The directors are responsible for the preparation and presentation of this interim financial report in accordance with International Accounting Standard 34.

Our responsibility is to express a conclusion, based on our review, on this interim financial report and to report our conclusion solely to you, as a body, in accordance with our agreed terms of engagement, and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report.

### **SCOPE OF REVIEW**

We conducted our review in accordance with Hong Kong Standard on Review Engagements 2410, *Review of interim financial information performed by the independent auditor of the entity* as issued by the Hong Kong Institute of Certified Public Accountants. A review of interim financial report consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Hong Kong Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly we do not express an audit opinion.

### **CONCLUSION**

Based on our review, nothing has come to our attention that causes us to believe that the interim financial report as at June 30, 2026 is not prepared, in all material respects, in accordance with International Accounting Standard 34 *Interim financial reporting*.

#### **KPMG**

*Certified Public Accountants*  
8th Floor, Prince's Building  
10 Chater Road  
Central, Hong Kong

August 28, 2026

# Consolidated Statement of Profit or Loss

For the six months ended June 30, 2026 – unaudited (Expressed in Renminbi)

|                                                                                                  |      | Six months ended June 30, |                 |
|--------------------------------------------------------------------------------------------------|------|---------------------------|-----------------|
|                                                                                                  | Note | 2026<br>RMB'000           | 2025<br>RMB'000 |
| <b>Revenue</b>                                                                                   | 3    | <b>319,316</b>            | 149,383         |
| Cost of sales                                                                                    |      | (114,688)                 | (55,533)        |
| <b>Gross profit</b>                                                                              |      | <b>204,628</b>            | 93,850          |
| Research and development expenses                                                                |      | (53,841)                  | (96,502)        |
| Administrative expenses                                                                          |      | (26,498)                  | (39,354)        |
| Selling and marketing expenses                                                                   |      | (87,460)                  | (58,727)        |
| Impairment loss on trade receivables, other receivables<br>and contract assets                   |      | (11,899)                  | (3,106)         |
| Other net (loss)/gain                                                                            | 4    | (28,333)                  | 6,443           |
| Fair value changes of financial assets measured at<br>fair value through profit or loss ("FVPL") |      | (15,223)                  | 8,709           |
| Share of loss of an associate                                                                    |      | (10)                      | (68)            |
| <b>Loss from operations</b>                                                                      |      | <b>(18,636)</b>           | (88,755)        |
| Finance costs                                                                                    |      | (618)                     | (310)           |
| <b>Loss before taxation</b>                                                                      | 5    | <b>(19,254)</b>           | (89,065)        |
| Income tax                                                                                       | 6    | –                         | (22)            |
| <b>Loss for the period</b>                                                                       |      | <b>(19,254)</b>           | (89,087)        |
| <b>Attributable to equity shareholders of the Company</b>                                        |      | <b>(19,254)</b>           | (89,087)        |
| <b>Loss per share</b>                                                                            | 7    |                           |                 |
| Basic and diluted (RMB)                                                                          |      | (0.05)                    | (0.25)          |

The notes on pages 48 to 60 form part of this interim financial report. There are no dividends payable to equity shareholders of the Company attributable to the profit for the period as set out in note 15(a).

# Consolidated Statement of Profit or Loss and Other Comprehensive Income

For the six months ended June 30, 2026 – unaudited *(Expressed in Renminbi)*

|                                                                                                                           | Six months ended June 30, |                 |
|---------------------------------------------------------------------------------------------------------------------------|---------------------------|-----------------|
|                                                                                                                           | 2026<br>RMB'000           | 2025<br>RMB'000 |
| <b>Loss for the period</b>                                                                                                | <b>(19,254)</b>           | (89,087)        |
| <b>Other comprehensive income for the period,<br/>net of nil tax</b>                                                      |                           |                 |
| Item that may be reclassified subsequently to profit or loss:                                                             |                           |                 |
| Exchange differences on translation of financial statements of<br>operations outside the Chinese Mainland, net of nil tax | <b>(1,153)</b>            | (261)           |
| <b>Total comprehensive income for the period and<br/>attributable to equity shareholders of the Company</b>               | <b>(20,407)</b>           | (89,348)        |

The notes on pages 48 to 60 form part of this interim financial report.

# Consolidated Statement of Financial Position

At June 30, 2026 – unaudited (Expressed in Renminbi)

|                                   | Note | At June 30,<br>2026<br>RMB'000 | At December 31,<br>2025<br>RMB'000 |
|-----------------------------------|------|--------------------------------|------------------------------------|
| <b>Non-current assets</b>         |      |                                |                                    |
| Property, plant and equipment     | 8    | 94,879                         | 42,050                             |
| Intangible assets                 |      | 186                            | 89                                 |
| Trade receivables                 | 10   | 19,855                         | 3,999                              |
| Interest in an associate          |      | 121                            | 131                                |
| Other non-current assets          |      | 9,465                          | 5,120                              |
|                                   |      | <b>124,506</b>                 | 51,389                             |
| <b>Current assets</b>             |      |                                |                                    |
| Inventories                       | 9    | 158,140                        | 136,110                            |
| Contract assets                   |      | 8,047                          | 13,076                             |
| Trade and other receivables       | 10   | 255,406                        | 213,454                            |
| Prepayments                       |      | 29,576                         | 26,405                             |
| Other current assets              | 11   | 110,118                        | 131,451                            |
| Financial assets measured at FVPL | 12   | 536,815                        | 727,814                            |
| Cash and cash equivalents         | 13   | 1,260,075                      | 86,041                             |
|                                   |      | <b>2,358,177</b>               | 1,334,351                          |
| <b>Current liabilities</b>        |      |                                |                                    |
| Trade and other payables          | 14   | 79,751                         | 135,474                            |
| Contract liabilities              |      | 7,847                          | 7,729                              |
| Lease liabilities                 |      | 10,860                         | 4,249                              |
| Provisions                        |      | 22,525                         | 16,993                             |
|                                   |      | <b>120,983</b>                 | 164,445                            |

## Consolidated Statement of Financial Position

At June 30, 2026 – unaudited (Expressed in Renminbi)

|                                              | Note | At June 30,<br>2026<br>RMB'000 | At December 31,<br>2025<br>RMB'000 |
|----------------------------------------------|------|--------------------------------|------------------------------------|
| <b>Net current assets</b>                    |      | <b>2,237,194</b>               | 1,169,906                          |
| <b>Total assets less current liabilities</b> |      | <b>2,361,700</b>               | 1,221,295                          |
| <b>Non-current liabilities</b>               |      |                                |                                    |
| Contract liabilities                         |      | <b>10,723</b>                  | 7,813                              |
| Lease liabilities                            |      | <b>31,948</b>                  | 5,642                              |
| Deferred income                              |      | <b>9,127</b>                   | 9,130                              |
|                                              |      | <b>51,798</b>                  | 22,585                             |
| <b>NET ASSETS</b>                            |      | <b>2,309,902</b>               | 1,198,710                          |
| <b>CAPITAL AND RESERVES</b>                  | 15   |                                |                                    |
| Share capital                                |      | <b>391,881</b>                 | 360,000                            |
| Reserves                                     |      | <b>1,918,021</b>               | 838,710                            |
| <b>TOTAL EQUITY</b>                          |      | <b>2,309,902</b>               | 1,198,710                          |

Approved and authorized for issue by the board of directors on August 28, 2026.

Dr. Wang Jianchen  
Chairman of the board

Dr. Gao Yuanqian  
Executive Director

The notes on pages 48 to 60 form part of this interim financial report.

# Consolidated Statement of Changes in Equity

For the six months ended June 30, 2026 – unaudited *(Expressed in Renminbi)*

| Note                                                                 | Attributable to equity shareholders |                          |                             |                          |                               |                         |
|----------------------------------------------------------------------|-------------------------------------|--------------------------|-----------------------------|--------------------------|-------------------------------|-------------------------|
|                                                                      | Share capital<br>RMB'000            | Share premium<br>RMB'000 | Exchange reserve<br>RMB'000 | Other reserve<br>RMB'000 | Accumulated losses<br>RMB'000 | Total equity<br>RMB'000 |
| <b>Balance at January 1, 2025</b>                                    | 360,000                             | 1,556,310                | 88                          | 64,682                   | (721,124)                     | 1,259,956               |
| <b>Changes in equity for the six months ended June 30, 2025:</b>     |                                     |                          |                             |                          |                               |                         |
| Loss for the period                                                  | -                                   | -                        | -                           | -                        | (89,087)                      | (89,087)                |
| Other comprehensive income                                           | -                                   | -                        | (261)                       | -                        | -                             | (261)                   |
| Total comprehensive income                                           | -                                   | -                        | (261)                       | -                        | (89,087)                      | (89,348)                |
| Equity-settled share-based transactions                              | -                                   | -                        | -                           | 13,976                   | -                             | 13,976                  |
| <b>Balance at June 30, 2025</b>                                      | 360,000                             | 1,556,310                | (173)                       | 78,658                   | (810,211)                     | 1,184,584               |
| <b>Changes in equity for the six months ended December 31, 2025:</b> |                                     |                          |                             |                          |                               |                         |
| Profit for the period                                                | -                                   | -                        | -                           | -                        | 480                           | 480                     |
| Other comprehensive income                                           | -                                   | -                        | (522)                       | -                        | -                             | (522)                   |
| Total comprehensive income                                           | -                                   | -                        | (522)                       | -                        | 480                           | (42)                    |
| Equity-settled share-based transactions                              | -                                   | -                        | -                           | 14,168                   | -                             | 14,168                  |
| <b>Balance at December 31, 2025</b>                                  | 360,000                             | 1,556,310                | (695)                       | 92,826                   | (809,731)                     | 1,198,710               |

## Consolidated Statement of Changes in Equity

For the six months ended June 30, 2026 – unaudited (*Expressed in Renminbi*)

|                                                                                                            | Note  | Attributable to equity shareholders |                 |               |                  |               |                    |
|------------------------------------------------------------------------------------------------------------|-------|-------------------------------------|-----------------|---------------|------------------|---------------|--------------------|
|                                                                                                            |       | Share capital                       | Treasury shares | Share premium | Exchange reserve | Other reserve | Accumulated losses |
|                                                                                                            |       | RMB'000                             | RMB'000         | RMB'000       | RMB'000          | RMB'000       | RMB'000            |
| <b>Balance at January 1, 2026</b>                                                                          |       | 360,000                             | -               | 1,556,310     | (695)            | 92,826        | (809,731)          |
| <b>Changes in equity for the six months ended June 30, 2026:</b>                                           |       |                                     |                 |               |                  |               |                    |
| Loss for the period                                                                                        |       | -                                   | -               | -             | -                | -             | (19,254)           |
| Other comprehensive income                                                                                 |       | -                                   | -               | -             | (1,153)          | -             | -                  |
| Total comprehensive income                                                                                 |       | -                                   | -               | -             | (1,153)          | -             | (19,254)           |
| Issuance of H shares upon global offering and exercise of the over-allotment option, net of issuance costs | 15(b) | 31,881                              | -               | 1,160,485     | -                | -             | -                  |
| Repurchase of H shares                                                                                     | 15(c) | -                                   | (59,183)        | -             | -                | -             | -                  |
| Equity-settled share-based transactions                                                                    |       | -                                   | -               | -             | -                | (1,584)       | -                  |
| <b>Balance at June 30, 2026</b>                                                                            |       | 391,881                             | (59,183)        | 2,716,795     | (1,848)          | 91,242        | (828,985)          |

The notes on pages 48 to 60 form part of this interim financial report.

# Condensed Consolidated Cash Flow Statement

For the six months ended June 30, 2026 – unaudited (Expressed in Renminbi)

|                                                                                                                              | Six months ended June 30, |                 |
|------------------------------------------------------------------------------------------------------------------------------|---------------------------|-----------------|
|                                                                                                                              | 2026<br>RMB'000           | 2025<br>RMB'000 |
| <b>Operating activities</b>                                                                                                  |                           |                 |
| Cash used in operations                                                                                                      | (116,907)                 | (96,910)        |
| <b>Net cash used in operating activities</b>                                                                                 | (116,907)                 | (96,910)        |
| <b>Investing activities</b>                                                                                                  |                           |                 |
| Payment for purchase of property, plant and equipment                                                                        | (12,533)                  | (1,572)         |
| Payment for purchase of intangible assets                                                                                    | (174)                     | (84)            |
| Payment for purchase of financial assets                                                                                     | (431,709)                 | (600,383)       |
| Proceeds from disposal of financial assets                                                                                   | 659,874                   | 677,612         |
| Interest received                                                                                                            | 11,173                    | 597             |
| Payment for investment in an associate                                                                                       | –                         | (222)           |
| <b>Net cash generated from investing activities</b>                                                                          | 226,631                   | 75,948          |
| <b>Financing activities</b>                                                                                                  |                           |                 |
| Net proceeds from issuance of H shares upon global offering and exercise of the over-allotment option, net of issuance costs | 1,184,257                 | –               |
| Payment for repurchase of H shares                                                                                           | (59,183)                  | –               |
| Deposit for repurchase of H shares                                                                                           | (27,846)                  | –               |
| Listing expenses paid                                                                                                        | (1,133)                   | (399)           |
| Lease deposits paid                                                                                                          | (3,862)                   | –               |
| Lease deposits received                                                                                                      | 2,811                     | –               |
| Payment of capital element of lease liabilities                                                                              | (4,917)                   | (3,516)         |
| Payment of interest element of lease liabilities                                                                             | (618)                     | (310)           |
| <b>Net cash generated from/(used in) financing activities</b>                                                                | 1,089,509                 | (4,225)         |
| <b>Net increase/(decrease) in cash and cash equivalents</b>                                                                  | 1,199,233                 | (25,187)        |
| <b>Cash and cash equivalents at the beginning of the period</b>                                                              | 86,041                    | 119,811         |
| <b>Effect of foreign exchange rate changes</b>                                                                               | (32,274)                  | (167)           |
| <b>Cash and cash equivalents at the end of the period</b>                                                                    | 1,253,000                 | 94,457          |

The notes on pages 48 to 60 form part of this interim financial report.

# Notes to the Unaudited Interim Financial Report

(Expressed in Renminbi unless otherwise indicated)

## 1 BASIS OF PREPARATION

This interim financial report has been prepared in accordance with the applicable disclosure provisions of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, including compliance with International Accounting Standard (“IAS”) 34, *Interim financial reporting*, issued by the International Accounting Standards Board (“IASB”). It was authorized for issue on August 28, 2026.

The interim financial report has been prepared in accordance with the same accounting policies adopted in the 2025 annual financial statements, except for the accounting policy changes that are expected to be reflected in the 2026 annual financial statements. Details of any changes in accounting policies are set out in note 2.

The preparation of an interim financial report in conformity with IAS 34 requires management to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, income and expenses on a year-to-date basis. Actual results may differ from these estimates.

This interim financial report contains condensed consolidated financial statements and selected explanatory notes. The notes include an explanation of events and transactions that are significant to an understanding of the changes in financial position and performance of the Group since the 2025 annual financial statements. The condensed consolidated interim financial statements and the accompanying notes do not include all of the information required for a full set of financial statements prepared in accordance with IFRS Accounting Standards.

The interim financial report is unaudited, but has been reviewed by KPMG in accordance with Hong Kong Standard on Review Engagements 2410, *Review of interim financial information performed by the independent auditor of the entity*, issued by the Hong Kong Institute of Certified Public Accountants (the “HKICPA”). KPMG’s independent review report to the Board of Directors is included on page 40.

## 2 CHANGES IN ACCOUNTING POLICIES

The IASB has issued a number of amendments to IFRS Accounting Standards that are first effective for the current accounting period. Of these, only the amendments to IFRS 9, *Financial instruments* and IFRS 7, *Financial instruments: Disclosures – Amendments to the classification and measurement of financial instruments*, are relevant to the Group’s financial statements. None of these developments have had a material effect on the financial statements. The Group has not applied any new standard or interpretation that is not yet effective for the current accounting period.

# Notes to the Unaudited Interim Financial Report

(Expressed in Renminbi unless otherwise indicated)

## 3 REVENUE AND SEGMENT REPORTING

The Group derives revenue principally from the sales of surgical robot systems, instruments and accessories, and provision of services.

For the purpose of resource allocation and performance assessment, the Group's most senior executive management reviews the consolidated results when making decisions about allocating resources and assessing performance of the Group as a whole and hence, the Group has only one reportable segment and no further analysis of this single segment is presented.

### DISAGGREGATION OF REVENUE

Disaggregation of revenue from contracts with customers by major products or service lines and timing of revenue recognition is as follows:

|                                                                         | Six months ended June 30, |                 |
|-------------------------------------------------------------------------|---------------------------|-----------------|
|                                                                         | 2026<br>RMB'000           | 2025<br>RMB'000 |
| <b>Revenue from contract with customers within the scope of IFRS 15</b> |                           |                 |
| – Sales of medical devices and accessories – point in time              | 318,164                   | 149,048         |
| – Service income – over time                                            | 1,152                     | 335             |
|                                                                         | <b>319,316</b>            | 149,383         |

Revenue from each major customer which accounted for 10% or more of the Group's revenue is set out below:

|            | Six months ended June 30, |                 |
|------------|---------------------------|-----------------|
|            | 2026<br>RMB'000           | 2025<br>RMB'000 |
| Customer A | 39,280                    | Not applicable* |
| Customer B | Not applicable*           | 26,036          |
| Customer C | 32,900                    | 15,141          |

\* Less than 10% of the Group's interim revenue.

# Notes to the Unaudited Interim Financial Report

(Expressed in Renminbi unless otherwise indicated)

## 3 REVENUE AND SEGMENT REPORTING (continued)

### DISAGGREGATION OF REVENUE (continued)

The following table sets out information about the geographical location of the Group's revenue from external customers. The geographical location is based on the place of registration of the customers.

|                                                            | Revenues from external customers |                 |
|------------------------------------------------------------|----------------------------------|-----------------|
|                                                            | Six months ended June 30,        |                 |
|                                                            | 2026<br>RMB'000                  | 2025<br>RMB'000 |
| <b>Disaggregated by geographical location of customers</b> |                                  |                 |
| – Chinese mainland                                         | 96,498                           | 88,687          |
| – Asia (other than Chinese Mainland)                       | 112,899                          | 23,755          |
| – Europe                                                   | 79,449                           | 24,319          |
| – Other countries*                                         | 30,470                           | 12,622          |
|                                                            | <b>319,316</b>                   | <b>149,383</b>  |

\* Each continent accounts for less than 10% of the Group's interim revenue.

## 4 OTHER NET (LOSS)/GAIN

|                                                                | Six months ended June 30, |                 |
|----------------------------------------------------------------|---------------------------|-----------------|
|                                                                | 2026<br>RMB'000           | 2025<br>RMB'000 |
| Interest income on financial assets measured at amortized cost | 13,352                    | 2,333           |
| Investment income on financial assets measured at FVPL         | 845                       | 3,792           |
| Government grants                                              | 4,854                     | 526             |
| Net foreign exchange loss                                      | (46,983)                  | (238)           |
| Others                                                         | (401)                     | 30              |
|                                                                | <b>(28,333)</b>           | <b>6,443</b>    |

## Notes to the Unaudited Interim Financial Report

(Expressed in Renminbi unless otherwise indicated)

### 5 LOSS BEFORE TAXATION

Loss before taxation is arrived at after charging:

#### (A) FINANCE COSTS

|                               | Six months ended June 30, |                 |
|-------------------------------|---------------------------|-----------------|
|                               | 2026<br>RMB'000           | 2025<br>RMB'000 |
| Interest on lease liabilities | 618                       | 310             |

#### (B) OTHER ITEMS

|                                                           | Six months ended June 30, |                 |
|-----------------------------------------------------------|---------------------------|-----------------|
|                                                           | 2026<br>RMB'000           | 2025<br>RMB'000 |
| Amortization of intangible assets                         | 77                        | 752             |
| Depreciation charge                                       |                           |                 |
| – owned property, plant and equipment                     | 5,810                     | 7,252           |
| – leasehold improvements                                  | 2,179                     | 2,401           |
| – right-of-use assets                                     | 5,429                     | 3,361           |
|                                                           | 13,418                    | 13,014          |
| Inventory write-down and losses net of reversals (note 9) | 923                       | 469             |
| Listing expenses                                          | –                         | 16,764          |

# Notes to the Unaudited Interim Financial Report

(Expressed in Renminbi unless otherwise indicated)

## 6 INCOME TAX

Pursuant to the PRC Income Tax Laws, the Company and its subsidiaries in the Chinese Mainland are liable to PRC Corporate Income Tax ("CIT") at a rate of 25% except that the Company is accredited as a "high and new technology enterprise" in 2024 and accordingly enjoys a preferential enterprise income tax rate of 15% during the six months ended June 30, 2026 (six months ended June 30, 2025: 15%).

The provision for Hong Kong Profits Tax is subject to Hong Kong's two-tiered profits tax regime, under which the tax rate is 8.25% for assessable profits on the first Hong Kong Dollars ("HKD") 2,000,000 and 16.5% for any assessable profits in excess of HKD2,000,000.

The Group has not recognized deferred tax assets in respect of cumulative unused tax losses as it is not probable that future taxable profits against which the losses can be utilized will be available in the relevant tax jurisdiction and entity.

## 7 LOSS PER SHARE

### (A) BASIC LOSS PER SHARE

The calculation of basic loss per share is based on the loss attributable to equity shareholders of the Company of RMB19,254,000 for the six months ended June 30, 2026 (six months ended June 30, 2025: RMB89,087,000) and the weighted average of 389,808,000 ordinary shares in issue during the six months ended June 30, 2026 (six months ended June 30, 2025: 360,000,000 ordinary shares).

*Weighted average number of ordinary shares*

|                                                       | Six months ended June 30, |              |
|-------------------------------------------------------|---------------------------|--------------|
|                                                       | 2026<br>'000              | 2025<br>'000 |
| Issued ordinary shares at January 1                   | 360,000                   | 360,000      |
| Effects of shares issuance                            | 29,912                    | —            |
| Effects of shares repurchase                          | (104)                     | —            |
| Weighted average number of ordinary shares at June 30 | 389,808                   | 360,000      |

### (B) DILUTED LOSS PER SHARE

The Group did not have any outstanding dilutive potential ordinary shares for the six months ended June 30, 2026 and 2025.

Accordingly, diluted loss per share for the six months ended June 30, 2026 and 2025 are the same as basic loss per share.

## Notes to the Unaudited Interim Financial Report

(Expressed in Renminbi unless otherwise indicated)

### 8 PROPERTY, PLANT AND EQUIPMENT

During the six months ended June 30, 2026, the Group entered into a number of lease agreements for the use of vehicles and office building, and therefore recognized the additions to right-of-use assets of RMB37,835,000 (six months ended June 30, 2025: nil).

During the six months ended June 30, 2026, the Group acquired items of property, plant and equipment (excluding right-of-use assets) with a cost of RMB12,561,000 (six months ended June 30, 2025: RMB1,370,000).

### 9 INVENTORIES

During the six months ended June 30, 2026, the Group has made inventory write down of RMB923,000 (six months ended June 30, 2025: RMB469,000).

### 10 TRADE AND OTHER RECEIVABLES

As of the end of the reporting period, the ageing analysis of trade receivables (which are included in trade and other receivables), based on the date of revenue recognition and net of loss allowance, is as follows:

|                                             | As at<br>June 30,<br>2026<br>RMB'000 | As at<br>December 31,<br>2025<br>RMB'000 |
|---------------------------------------------|--------------------------------------|------------------------------------------|
| Within 3 months                             | 162,523                              | 153,051                                  |
| 3 to 12 months                              | 83,507                               | 32,987                                   |
| Over 1 year                                 | 6,446                                | 2,266                                    |
| Trade receivables, net of loss allowance    | 252,476                              | 188,304                                  |
| Other receivables, net of loss allowance    | 22,785                               | 29,149                                   |
| Financial assets measured at amortized cost | 275,261                              | 217,453                                  |
| <b>Representing</b>                         |                                      |                                          |
| Current portion                             | 255,406                              | 213,454                                  |
| Non-current portion                         | 19,855                               | 3,999                                    |

All of the current portion of trade and other receivables are due within one year from the date of billing.

# Notes to the Unaudited Interim Financial Report

(Expressed in Renminbi unless otherwise indicated)

## 11 OTHER CURRENT ASSETS

|                                    | As at<br>June 30,<br>2026<br>RMB'000 | As at<br>December 31,<br>2025<br>RMB'000 |
|------------------------------------|--------------------------------------|------------------------------------------|
| Term deposit                       | 59,934                               | 109,033                                  |
| Value-added tax recoverable        | 22,338                               | 18,832                                   |
| Deposit for repurchase of H shares | 27,846                               | –                                        |
| Listing expenses to be capitalized | –                                    | 3,586                                    |
|                                    | 110,118                              | 131,451                                  |

## 12 FINANCIAL ASSETS MEASURED AT FVPL

|                                                | As at<br>June 30,<br>2026<br>RMB'000 | As at<br>December 31,<br>2025<br>RMB'000 |
|------------------------------------------------|--------------------------------------|------------------------------------------|
| Net value-based wealth management products (i) | 490,015                              | 727,814                                  |
| Private funds (ii)                             | 46,800                               | –                                        |
|                                                | 536,815                              | 727,814                                  |

Notes:

- (i) The net value-based wealth management products are issued by banks in Chinese mainland with a floating return which will be paid together with the principal on the maturity date within 1 year.
- (ii) The investment in private equity fund was principally engaged in investment in Hong Kong listed companies.

## Notes to the Unaudited Interim Financial Report

(Expressed in Renminbi unless otherwise indicated)

### 13 CASH AND CASH EQUIVALENTS

|                          | As at<br>June 30,<br>2026<br>RMB'000 | As at<br>December 31,<br>2025<br>RMB'000 |
|--------------------------|--------------------------------------|------------------------------------------|
| Cash at bank and on hand | 1,253,000                            | 86,041                                   |
| Restricted cash          | 7,075                                | –                                        |
|                          | 1,260,075                            | 86,041                                   |

As at June 30, 2026, cash and cash equivalents placed with banks in Chinese Mainland amounted to RMB742,831,000 (December 31, 2025: RMB80,236,000). Remittance of funds out of Chinese Mainland is subject to relevant rules and regulations of foreign exchange control promulgated by the PRC government.

### 14 TRADE AND OTHER PAYABLES

As of the end of the reporting period, the ageing analysis of trade payables (which are included in trade and other payables), based on the invoice date, is as follows:

|                                    | As at<br>June 30,<br>2026<br>RMB'000 | As at<br>December 31,<br>2025<br>RMB'000 |
|------------------------------------|--------------------------------------|------------------------------------------|
| Within 3 months                    | 19,937                               | 21,630                                   |
| 3 to 12 months                     | 226                                  | 1,007                                    |
| Over 1 year                        | 178                                  | 162                                      |
| Trade payables                     | 20,341                               | 22,799                                   |
| Accrued payroll                    | 25,615                               | 37,040                                   |
| Other payables and accrued charges | 33,795                               | 75,635                                   |
|                                    | 79,751                               | 135,474                                  |

# Notes to the Unaudited Interim Financial Report

(Expressed in Renminbi unless otherwise indicated)

## 15 CAPITAL AND RESERVES

### (A) DIVIDENDS

No interim dividends have been declared or paid by the Company during the six months ended June 30, 2026 (six months ended June 30, 2025: nil).

### (B) SHARE CAPITAL

|                                                                                                                      | Number of<br>ordinary<br>shares<br>'000 | Nominal<br>value of fully<br>paid shares<br>RMB'000 |
|----------------------------------------------------------------------------------------------------------------------|-----------------------------------------|-----------------------------------------------------|
| <b>Ordinary shares issued and fully paid:</b>                                                                        |                                         |                                                     |
| At January 1, 2025, June 30, 2025 and January 1, 2026                                                                | 360,000                                 | 360,000                                             |
| Issuance of H shares upon global offering and exercise of<br>the over-allotment option, net of issuance costs (Note) | 31,881                                  | 31,881                                              |
| At June 30, 2026                                                                                                     | 391,881                                 | 391,881                                             |

Note: On January 8, 2026, the Company had newly issued 27,722,200 H shares at HKD43.24 per H share with a par value of RMB1.00 each by way of the initial public offering to investors. On February 9, 2026, pursuant to the full exercise of the over-allotment option of the initial public offering, the Company allotted and issued an additional 4,158,300 H shares at the offer price of HKD43.24 per H share.

The total gross proceeds from the new H shares issued were approximately RMB1,240,558,000 (equivalent to HKD1,378,513,000). The respective share capital amount was RMB31,880,500, and capital reserve was approximately RMB1,160,485,000, net of issuance costs. The issuance costs paid mainly include share underwriting fees and commissions and professional fees paid to legal, accounting, other advisors and other related costs for their services rendered, which are incremental costs directly attributable to the issuance of the new H shares. These costs amounting to RMB48,192,000 were treated as a deduction against the capital reserve arising from the issuance.

# Notes to the Unaudited Interim Financial Report

(Expressed in Renminbi unless otherwise indicated)

## 15 CAPITAL AND RESERVES (continued)

### (C) PURCHASE OF OWN SHARES

During the interim period, the Company repurchased its own shares on The Stock Exchange of Hong Kong Limited, as follows:

| Month/year | Number of<br>H shares<br>repurchased | Highest<br>price paid<br>per H share<br>HKD | Lowest<br>price paid<br>per H share<br>HKD | Aggregate<br>price paid<br>HKD'000 |
|------------|--------------------------------------|---------------------------------------------|--------------------------------------------|------------------------------------|
| June 2026  | 1,818,900                            | 39.00                                       | 33.78                                      | 68,004                             |

## 16 FINANCIAL RISK MANAGEMENT AND FAIR VALUES OF FINANCIAL INSTRUMENTS

### (A) FINANCIAL ASSETS AND LIABILITIES MEASURED AT FAIR VALUE

#### (i) Fair value hierarchy

The following table presents the fair value of the Group's financial instruments measured at the end of each reporting period on a recurring basis, categorized into the three-level fair value hierarchy as defined in IFRS 13, *Fair value measurement*. The level into which a fair value measurement is classified is determined with reference to the observability and significance of the inputs used in the valuation technique as follows:

- Level 1 valuations: Fair value measured using only Level 1 inputs i.e. unadjusted quoted prices in active markets for identical assets or liabilities at the measurement date
- Level 2 valuations: Fair value measured using Level 2 inputs i.e. observable inputs which fail to meet Level 1, and not using significant unobservable inputs. Unobservable inputs are inputs for which market data are not available
- Level 3 valuations: Fair value measured using significant unobservable inputs

# Notes to the Unaudited Interim Financial Report

(Expressed in Renminbi unless otherwise indicated)

## 16 FINANCIAL RISK MANAGEMENT AND FAIR VALUES OF FINANCIAL INSTRUMENTS (continued)

### (A) FINANCIAL ASSETS AND LIABILITIES MEASURED AT FAIR VALUE (continued)

#### (i) Fair value hierarchy (continued)

The following table presents the Group's financial assets and liabilities that are measured at fair value at the end of each reporting dates:

|                                              | Fair value at<br>June 30,<br>2026<br>RMB'000 | Fair value measurements as at<br>June 30, 2026 categorized into |                    |                    |
|----------------------------------------------|----------------------------------------------|-----------------------------------------------------------------|--------------------|--------------------|
|                                              |                                              | Level 1<br>RMB'000                                              | Level 2<br>RMB'000 | Level 3<br>RMB'000 |
| <b>Recurring fair value measurement</b>      |                                              |                                                                 |                    |                    |
| – Net value-based wealth management products | 490,015                                      | –                                                               | 490,015            | –                  |
| – Private fund                               | 46,800                                       | –                                                               | 46,800             | –                  |
|                                              | <b>536,815</b>                               | <b>–</b>                                                        | <b>536,815</b>     | <b>–</b>           |

|                                              | Fair value at<br>December 31,<br>2025<br>RMB'000 | Fair value measurements as at<br>December 31, 2025 categorized into |                    |                    |
|----------------------------------------------|--------------------------------------------------|---------------------------------------------------------------------|--------------------|--------------------|
|                                              |                                                  | Level 1<br>RMB'000                                                  | Level 2<br>RMB'000 | Level 3<br>RMB'000 |
| <b>Recurring fair value measurement</b>      |                                                  |                                                                     |                    |                    |
| – Net value-based wealth management products | 727,814                                          | –                                                                   | 727,814            | –                  |

During the six months ended June 30, 2026, there were no transfers between Level 1 and Level 2, or transfers into or out of Level 3 (December 31, 2025: nil). The Group's policy is to recognize transfers between levels of fair value hierarchy as at the end of the reporting period in which they occur.

## Notes to the Unaudited Interim Financial Report

(Expressed in Renminbi unless otherwise indicated)

### 16 FINANCIAL RISK MANAGEMENT AND FAIR VALUES OF FINANCIAL INSTRUMENTS (continued)

#### (A) FINANCIAL ASSETS AND LIABILITIES MEASURED AT FAIR VALUE (continued)

##### (ii) Valuation techniques and inputs used in Level 2 fair value measurement:

The fair value of net value-based wealth management products in Level 2 is determined by expected yield that links to underlying asset with observable inputs.

The fair value of private fund is determined based on the investment statements provided by the investment management of private funds.

##### (iii) Fair value of financial assets and liabilities carried at other than fair value

The carrying amounts of the Group's financial instruments carried at amortized cost were not materially different from their fair values as at June 30, 2026 and December 31, 2025.

### 17 COMMITMENTS

Commitments outstanding as at June 30, 2026 not provided for in the interim financial report:

|                                                                  | As at<br>June 30,<br>2026<br>RMB'000 | As at<br>December 31,<br>2025<br>RMB'000 |
|------------------------------------------------------------------|--------------------------------------|------------------------------------------|
| Contracted for<br>– acquisition of property, plant and equipment | 20,711                               | 152                                      |

### 18 MATERIAL RELATED PARTY TRANSACTIONS

There is no material related party transaction for the six months ended June 30, 2026 and 2025, except for key management personnel remuneration. No material amounts from related parties were outstanding as at June 30, 2026 and December 31, 2025.

# Notes to the Unaudited Interim Financial Report

(Expressed in Renminbi unless otherwise indicated)

## 19 POSSIBLE IMPACT OF AMENDMENTS, NEW STANDARDS, AND INTERPRETATIONS ISSUED BUT NOT YET EFFECTIVE FOR THE SIX MONTHS ENDED JUNE 30, 2026

A number of amendments and new standards are not yet mandatory for annual periods beginning January 1, 2026. Earlier application is permitted; however, the Group has not early adopted any new or amended standards in preparing this interim financial report.

The following updates the information provided in the last annual financial statements about the possible impacts of IFRS 18 which may have a significant impact on the Group's consolidated financial statements when adopted.

### **IFRS 18, PRESENTATION AND DISCLOSURE IN FINANCIAL STATEMENTS**

IFRS 18 will replace IAS 1, *Presentation of financial statements*, and is first effective for annual reporting periods beginning on or after January 1, 2027.

IFRS 18 introduces new requirements for presentation and disclosure in financial statements, including new categories and defined subtotals in the statement of profit or loss, enhanced requirements for aggregation and disaggregation of information, and specific disclosures about management-defined performance measures. The Group is assessing the expected impact that the initial application of IFRS 18 will have on its consolidated financial statements.

The Group expects that the adoption of IFRS 18 will not change the Group's net assets or net profit. However, it is expected to affect the presentation of the Group's consolidated statement of profit or loss and related note disclosures. The Group expects to apply the new standard from its mandatory effective date of January 1, 2027. Retrospective application is required, and the comparative information for the financial year ending December 31, 2026 will be restated in accordance with IFRS 18.

# Definitions

In this interim report, the following expressions have the meanings set out below unless the context requires otherwise:

|                                         |                                                                                                                                                                                                                                                                         |
|-----------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| “Articles of Association” or “Articles” | the articles of association of our Company, as amended from time to time                                                                                                                                                                                                |
| “Audit Committee”                       | the audit committee of the Board                                                                                                                                                                                                                                        |
| “Board”                                 | the board of Directors of the Company                                                                                                                                                                                                                                   |
| “CE Marking”                            | a certification mark that indicates conformity with health, safety and environmental protection standards for products sold within the European Economic Area                                                                                                           |
| “CG Code”                               | the Corporate Governance Code as set out in Appendix C1 to the Listing Rules                                                                                                                                                                                            |
| “Class III Grade A hospitals”           | top-tier hospitals in China. Hospitals in China can be categorized into Class I, II and III in terms of service quality, management level, medical equipment, hospital size and medical technology. Each class can be further divided into Grade A, Grade B and Grade C |
| “Class III medical device”              | the medical devices that are considered high-risk and whose safety and effectiveness must be strictly regulated in accordance with the classification rules promulgated by the NMPA                                                                                     |
| “Company” or “our Company”              | Shenzhen Edge Medical Co., Ltd. (深圳市精鋒醫療科技股份有限公司), a company incorporated in the People’s Republic of China, the H Shares of which are listed on the main board of the Stock Exchange (stock code: 2675)                                                                |
| “connected person(s)”                   | has the meaning ascribed thereto under the Listing Rules                                                                                                                                                                                                                |
| “Controlling Shareholders”              | has the meaning ascribed thereto under the Listing Rules and unless the context otherwise requires, refers to Dr. Wang, Dr. Gao and Xieli Chuangfeng                                                                                                                    |
| “Core Product(s)”                       | has the meaning ascribed to it in Chapter 18A of the Listing Rules; for the purposes of this report, our Core Products refer to, Edge Multi-Port Endoscopic Surgical Robot and Edge Single-Port Endoscopic Surgical Robot                                               |

## Definitions

|                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                             |
|------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| “Director(s)”                                                          | the director(s) of the Company                                                                                                                                                                                                                                                                                                                                                                              |
| “Employee Incentive Scheme”                                            | the employee incentive plan of our Company approved and adopted by our Board on January 20, 2019, and amended on January 4, 2022, the principal terms of which are set out in the section headed “Statutory and General Information – Further Information about our Directors, Supervisors, Senior Management and Substantial Shareholders – 5. Employee Incentive Scheme” in Appendix VI of the Prospectus |
| “EU”                                                                   | European Union                                                                                                                                                                                                                                                                                                                                                                                              |
| “Frost & Sullivan”                                                     | Frost & Sullivan (Beijing) Inc., Shanghai Branch Co., a global market research and consulting company, which is an independent third party of the Company                                                                                                                                                                                                                                                   |
| “Global Offering”                                                      | has the meaning ascribed to it in the Prospectus                                                                                                                                                                                                                                                                                                                                                            |
| “Group”, “our Group”,<br>“the Group”, “Edge Medical”,<br>or “we”, “us” | the Company and its subsidiaries from time to time                                                                                                                                                                                                                                                                                                                                                          |
| “HKD”, “HK\$” or “HK dollar”                                           | Hong Kong dollars, the lawful currency of Hong Kong                                                                                                                                                                                                                                                                                                                                                         |
| “Hong Kong”                                                            | the Hong Kong Special Administrative Region of the PRC                                                                                                                                                                                                                                                                                                                                                      |
| “H Shares”                                                             | overseas listed share(s) in the share capital of our Company with a nominal value of RMB1.0 each, which is/are subscribed for and traded in HK dollars and listed on the Stock Exchange                                                                                                                                                                                                                     |
| “Latest Practicable Date”                                              | September 18, 2026, being the latest practicable date prior to the publication of this interim report for ascertaining certain information contained herein                                                                                                                                                                                                                                                 |
| “Listing”                                                              | the listing of H Shares on the Main Board on the Listing Date                                                                                                                                                                                                                                                                                                                                               |
| “Listing Date”                                                         | January 8, 2026, being the date on which the H Shares were listed on the Main Board                                                                                                                                                                                                                                                                                                                         |

|                                                                    |                                                                                                                                                                         |
|--------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| “Listing Rules”                                                    | the Rules Governing the Listing of Securities on the Stock Exchange                                                                                                     |
| “Main Board”                                                       | the Main Board of the Stock Exchange                                                                                                                                    |
| “MIS” or<br>“minimally invasive surgery”                           | the surgical procedure performed through tiny incisions instead of a large opening                                                                                      |
| “Model Code”                                                       | the Model Code for Securities Transactions by Directors of Listed Issuers contained in Appendix C3 to the Listing Rules                                                 |
| “MP1000”                                                           | the first model of Edge Multi-Port Endoscopic Surgical Robot                                                                                                            |
| “NMPA”                                                             | National Medical Products Administration of the PRC                                                                                                                     |
| “Nomination Committee”                                             | the nomination committee of the Board                                                                                                                                   |
| “PRC”, “People’s Republic of China”, “Chinese Mainland” or “China” | the People’s Republic of China, excluding, for the purposes of this report, Hong Kong Special Administrative Region, the Macau Special Administrative Region and Taiwan |
| “Prospectus”                                                       | the prospectus issued by the Company on December 30, 2025 in connection with the Hong Kong public offering of the H Shares                                              |
| “R&D”                                                              | research and development                                                                                                                                                |
| “Remuneration Committee”                                           | the remuneration committee of the Board                                                                                                                                 |
| “Reporting Period”                                                 | the six months from January 1, 2026 to June 30, 2026                                                                                                                    |
| “RMB” or “Renminbi”                                                | Renminbi, the lawful currency of the PRC                                                                                                                                |
| “SFO”                                                              | the Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong, as amended, supplemented or otherwise modified from time to time                            |
| “Share(s)”                                                         | ordinary share(s) in the capital of our Company with a nominal value of RMB1.0 each                                                                                     |
| “Shareholder(s)”                                                   | holder(s) of Share(s)                                                                                                                                                   |
| “SP1000”                                                           | the first model of Edge Single-Port Endoscopic Surgical Robot                                                                                                           |
| “Stock Exchange”                                                   | The Stock Exchange of Hong Kong Limited                                                                                                                                 |
| “Supervisor(s)”                                                    | the supervisor(s) of our Company                                                                                                                                        |

## Definitions

|                              |                                                                                                                                                                                                                                                                                                                                                                      |
|------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| “Supervisory Committee”      | the supervisory committee of the Company                                                                                                                                                                                                                                                                                                                             |
| “treasury share(s)”          | has the meaning ascribed thereto under the Listing Rules                                                                                                                                                                                                                                                                                                             |
| “Unlisted Share(s)”          | ordinary share(s) in the capital of our Company with a nominal value of RMB1.0 each which are unlisted on any stock exchange                                                                                                                                                                                                                                         |
| “USD”, “US\$” or “US dollar” | United States dollar(s), the lawful currency of the United States of America                                                                                                                                                                                                                                                                                         |
| “Xieli Chuangfeng”           | Xieli Chuangfeng (Shenzhen) Technology Partnership (Limited Partnership) (協力創峰(深圳)科技合夥企業(有限合夥)) (previously known as Xieli Chuangfeng (Hainan) Technology Partnership (Limited Partnership) (協力創峰(海南)科技合夥企業(有限合夥))), a limited partnership established in the PRC on July 23, 2018 of which Dr. Wang is the sole general partner, and is our Controlling Shareholder |
| “%”                          | per cent                                                                                                                                                                                                                                                                                                                                                             |